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INTERCALATION-MEDIATED SYNTHESIS 
OF POLYMERS 
CROSS-REFERENCE TO RELATED 
APPLICATION 
This application claims priority to and benefit of U.S. 
provisional patent application No. 60/505,365 filed on Sep. 
23, 2003, which is incorporated by reference in its entirety. 
BACKGROUND 
1. Technical Field 
The present disclosure generally relates to methods and 
compositions for the synthesis of biopolymers, in particular 
natural or non-natural nucleic acids and analogous poly-
mers. 
2. Related Art 
DNA and RNA oligonucleotides, and their structural 
analogs, have found numerous applications as diagnostic 
and therapeutic agents. Nucleic acids are the polymers used 
by living organisms for the storage of genetic information, 
and are thus a primary therapeutic target for the treatment of 
genetic and acquired diseases, and for vaccine development. 
During the past decade, interest in anti-sense and anti-gene 
therapy has motivated the development of DNA and RNA 
molecules that bind at specific points within the human 
genome or to specific messenger RNA sequences. More 
recently, the discovery of small RNA molecules that natu-
rally interfere with gene expression has presented additional 
possibilities for how RNA may also be used to treat acquired 
and genetic diseases. Thus, methods to prepare RNA, DNA, 
and polymers in large scale are of great importance to the 
medical field for drug development and will soon be for use 
as therapeutics. 
Living organisms, including humans, have developed 
protective mechanisms to degrade foreign nucleic acids that 
gain entry to the cells or the intercellular fluid of the 
organism. Such foreign, or exogenous, nucleic acids include 
RNA and DNA polymers introduced by naturally-occurring 
viruses. These same anti-pathogen defense mechanisms, 
however, also limit the lifetime of nucleic acid polymers 
introduced into a human body for therapeutic purposes. 
Thus, it is of great importance to develop methods for the 
improved synthesis of non-natural structural analogs of 
RNA and DNA that can function in similar capacities as 
natural nucleic acid polymers, but that are not susceptible to 
the same modes of enzymatic degradation. Structural ana-
logs of the natural nucleic acids (or "non-natural" nucleic 
acids) include, but are not limited to, DNA and RNA-like 
polymers in which the natural backbone has been modified 
by the addition or removal of one or more chemical groups. 
These modifications range from the methylation of the 
ribose sugar, to the radical replacement of the backbone with 
a peptide-like backbone. Broadly defined, nucleic acids 
analogs, or non-natural nucleic acids, are any polymers that 
have chemical appendages to the polymer backbone similar 
in chemical structure to the natural nucleotide bases (i.e. A, 
adenine; C, cytosine; G, guanine; U, uridine; T, thymine) 
that allow the formation of base pairs for the transfer of 
nucleotide sequence information. Although the synthesis of 
natural nucleic acid polymers has become routine in many 
commercial and academic laboratories, the synthesis of 
non-natural nucleic acid polymers (i.e., synthetic analogs) is 
typically much more expensive and can require a substantial 
investment of time and resources for the development of a 
synthetic procedure for each new variation in nucleic acid 
2 
chemical structure. Thus, methods that can facilitate the 
synthesis of natural and non-natural nucleic acids are of 
great economic and medicinal importance. 
RNA and DNA molecules with a wide range of novel 
properties, including catalytic, molecular recognition and 
therapeutic activities, have been isolated from pools of RNA 
and DNA polymers, respectively, that initially contain a 
large number of random nucleotide sequences. This process 
is accomplished by multiple rounds of activity-based selec-
10 tion for nucleic acid molecules with a desired property from 
the pool of random sequences, followed by the enzymatic 
amplification of selected sequences using naturally-derived 
polymerases. Known as "in vitro selection" or "SELEX", 
this procedure represents one of the most powerful forms of 
15 combinatorial chemistry. 
The enzymatic amplification of nucleic acid sequences 
during each cycle of the SELEX procedure is an essential 
component of this procedure, as nucleic acid amplification 
leads to the exponential enrichment of sequences in a sample 
20 that have the desired molecular properties. The polymerases 
used to amplify nucleic acid molecules as part of the SELEX 
process were initially isolated from living organisms, and 
are still produced within host cells by fermentation. The 
amino acid sequences of these polymerases are either iden-
25 tical to that derived from a natural source, or are a geneti-
cally-modified variant of a natural polymerase. Natural 
polymerases or derivatives thereof cannot synthesize non-
natural nucleic acids. 
A process similar to SELEX for the selective amplifica-
30 tion of non-natural RNA-like polymers would undoubtedly 
produce molecules superior to RNA for many applications. 
For example, an RNA-like polymer with a backbone that is 
resistant to cleavage and degradation by natural ribonu-
cleases could be far more effective as an antibiotic because 
35 it would have a longer active time within the body. Another 
example would be the selection of a catalytic RNA-like 
polymer with a non-natural backbone that has charged 
groups with a pKa near neutrality. Such a catalyst would be 
sensitive to pH, and thus small changes in pH could be used 
40 to regulate catalytic activity. However, because naturally-
derived nucleic acid polymerases can only replicate RNA or 
DNA, the realization of in vitro selection with non-natural 
polymers will either require extensive evolution of existing 
polymerases, or the development of new methods for 
45 molecular replication. An editorial on the SELEX procedure 
by a pioneer of this technique clearly states that the ability 
to accomplish in vitro selection using naturally-derived 
polymerases comes with the severe limitation that selection 
can only be carried out with natural polymers (Szostak, 
50 1997). Thus, it is well appreciated by experts in this field that 
methods to replicate non-natural polymers would greatly 
expand the power of in vitro selection. Accordingly, the 
development of improved methods for the enzyme-free 
synthesis of nucleic acids and analogous polymers could be 
55 of great value to the fields of polymer chemistry, materials 
science, biotechnology and medicine. 
Those skilled in the art of nucleic acid synthesis have 
toiled for decades to improve methods for enzyme-free 
template-directed synthesis of nucleic acids with only mod-
60 est gains. For example, considerable effort has focused on 
the potential for inorganic cations to improve existing meth-
ods for the chemical coupling of nucleic acids in aqueous 
solution (Lohrmann et al, 1980; Rohatgi et al., 1996). In 
contrast, virtually no studies have investigated the possibil-
65 ity that a specific interaction between a small molecule and 
the nucleic acid bases could be used to enhance enzyme-free 
synthesis of nucleic acid polymers. 
US 7,368,560 B2 
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Thus, the collective body of research conducted by the 
scientific and medical communities demonstrates a need for 
more efficient methods for the chemical ligation of both 
natural and non-natural oligonucleotides in aqueous solu-
tion. Furthermore, there is a need for methods to efficiently 
couple nucleic acid polymers in solution using catalysts that 
are easily separated from the product molecules, so that the 
products can subsequently be used in therapeutic applica-
tions. An efficient, enzyme-free method for the coupling of 
both natural and non-natural nucleic acid oligonucleotides 10 
along a template strand would have substantial commercial 
value, as such methods will enable the in vitro selection of 
non-natural nucleic acid polymers with desirable therapeutic 
and catalytic properties. 
4 
molecules produced by the disclosed methods exhibit 
molecular recognition abilities that are useful for diagnostic 
purposes. 
A particular aspect provides a method of synthesizing a 
non-natural polynucleotide by combining in a fluid: a tem-
plate, a plurality of non-natural nucleic acid subunits, and an 
intercalator. Adjacent non-natural nucleic acid subunits 
associated with the template are then ligated, for example 
without using a polymerase or ligase. 
Another aspect provides a method of synthesizing a 
polynucleotide by combining in a fluid: a template compris-
ing a non-natural backbone or a non-natural nucleotide, a 
plurality of nucleic acid subunits, and an intercalator; and 
ligating adjacent nucleic acid subunits associated with the 
15 template. 
SUMMARY 
Aspects of the present disclosure generally provide com-
positions and methods for the synthesis of polymers, for 
example biopolymers such as nucleic acids. One aspect 20 
provides compositions and methods for synthesizing non-
natural biopolymers using a natural biopolymer template 
and at least one non-natural biopolymer subunit. Another 
aspect provides compositions and methods for synthesizing 
biopolymers using a non-natural biopolymer template and 25 
biopolymer subunits. Certain aspects provide enzyme-free 
methods of synthesizing biopolymers. 
Still other aspects provide improved methods for coupling 
nucleic acid oligonucleotides ("substrate oligonucleotides") 30 
into a longer oligonucleotide ("product oligonucleotide") 
where the sequence of the product oligonucleotide is gov-
erned by a preexisting DNA or RNA oligonucleotide ("tem-
plate strand"). For example, a solution can be prepared 
containing a small molecule that intercalates the base pairs 35 
of a structure formed between a template strand and sub-
strate oligonucleotides. A chemical or enzymatic method is 
used to couple the substrate oligonucleotides. The small 
molecule intercalator can be added to the reaction solution 
before or after the substrate and template oligonucleotides, 40 
or simultaneously with one of the oligonucleotides of the 
reaction. 
Still another aspect provides a method of synthesizing a 
biopolymer by combining a template, an intercalator, and 
biopolymer subunits in a fluid, wherein the intercalator has 
a structure according to Formula I: 
Formula! 
wherein each R1 is independently C, S, 0, or N; 
R2 is independently H, OH, N, carboxy, carbonyl, car-
bocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle, 
R3 and R4 are independently C, S, 0, or N; 
R5 and R6 are independently H, OH, N, carboxy, carbonyl, 
carbocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
In one aspect, the covalent linkage of mononucleotides 
and oligonucleotides into longer oligonucleotides is pro-
moted by the close structural match between the intercalat-
ing molecule and the base pairs of the substrate oligonucle-
otides and the template strand. Thus, some aspects of the 
disclosure are generally applicable to improving nucleic acid 
template-directed synthesis by virtually any chemical means 
45 substituted heterocycle; and ligating the subunits together to 
form a biopolymer that is complementary to at least a 
portion of the template. 
Another aspect provides a method of synthesizing a 
biopolymer by combining a template, an intercalator, and 
50 biopolymer subunits in a fluid, wherein the intercalator has 
a structure according to Formula II: 
in which assembly of substrate oligonucleotides along a 
template strand is mediated by nucleotide base-pairing. 
Certain aspects of the present disclosure are compatible with 
nucleic acid polymers having natural backbones, but can 
also be used with analogous polymers having a non-natural 
backbone. Thus, aspects of the disclosure also have the 55 
ability to improve the synthesis of natural nucleic acid 
polymers using a synthetic non-natural analog of RNA or 
DNA as a template strand. Additionally, aspects of the 
disclosure can improve the coupling of non-natural oligo-
nucleotides using natural RNA or DNA as a template strand. 60 
Other aspects of the present disclosure can also improve the 
synthesis of non-natural RNA-like oligonucleotides where a 
non-natural RNA-like oligonucleotide is used as a template 
strand. 
Some of the molecules produced using the disclosed 
compositions and methods can be biologically active and of 
therapeutic value. In another aspects of the disclosure, the 
Formula II 
wherein each R1 is independently C, S, 0, or N; and 
R2 is independently H, OH, N, carboxy, carbonyl, car-
65 bocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
US 7,368,560 B2 
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substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle; and ligating the subunits together to 
form a biopolymer that is complementary to at least a 
portion of the template. 
Yet another aspect provides a method of synthesizing a 
biopolymer by combining a template, an intercalator, and 
biopolymer subunits in a fluid, wherein the intercalator has 
a structure according to Formula III: 
Formula III 
6 
FIG. lB is a diagram of the molecular structure of two 
base pairs intercalated by the small molecule proflavine. 
FIG. 2A is a schematic representation of an exemplary 
embodiment of intercalation-mediated template-directed 
synthesis showing a template strand in solution with sub-
strate strands. The substrate strands are sufficiently short that 
the equilibrium amount of substrate strands bound to the 
template strand is extremely small. 
FIG. 2B is a schematic representation showing that the 
10 addition of an intercalating molecule to the solution facili-
tates the formation of a duplex between the template strand 
and substrate strands with Watson-Crick complementary 
sequences. 
FIG. 2C is a schematic representation showing chemical 
15 ligation used to join the backbones of substrate strands 
aligned along the template strand. 
wherein R2 is independently H, OH, N, carboxy, carbonyl, 
carbocyclo, substituted carbocyclo, cycloalkyl, substituted 
20 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle; and ligating the subunits together to 
form a biopolymer that is complementary to at least a 
25 portion of the template. 
FIG. 2D is a schematic representation showing that the 
intercalator can be removed from the reaction mixture as an 
early step in the process of product strand purification. 
FIG. 3A is a diagram of the molecular structure of an 
exemplary intercalator, proflavine. 
FIG. 3B is a space-filling model of the proflavine van der 
Waals surface. 
FIG. 3C is the chemical structure of a Watson-Crick A•T 
base pair. 
FIG. 3D is a space-filling model of the Watson-CrickA•T 
base pair. A black outline of the proflavine van der Waals 
surface is superimposed on the Watson-Crick base pairs to 
illustrate the close match between the shapes of these 
Another aspect provides a method of synthesizing a 
biopolymer by combining a template, an intercalator, and 
biopolymer subunits in a fluid, wherein the intercalator has 
a structure according to Formula IV: 
Formula IV 
wherein R1 is independently H, OH, N, carboxy, carbonyl, 
carbocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle; and ligating the subunits together to 
form a biopolymer that is complementary to at least a 
portion of the template. 
30 molecular structures. 
FIG. 3E is the chemical structure of a Watson-Crick G•C 
base pair. 
FIG. 3F is a space-filling model of the Watson-Crick G•C 
base pair. A black outline of the proflavine van der Waals 
35 surface is superimposed on the Watson-Crick base pairs to 
illustrate the close match between the shapes of these 
molecular structures 
FIGS. 4A-D are a schematic representation of an exem-
plary embodiment of intercalation-mediated primer exten-
40 sion. FIG. 4A shows a primer oligonucleotide bound to a 
template strand (template strand is shown in gray). The 
substrate oligonucleotides are sufficiently short that there is 
no appreciable equilibrium of substrate oligonucleotides 
bound to the template strand. FIG. 4B shows the introduc-
45 tion of an intercalating molecule to the solution facilitates 
the formation of duplex structures between the template 
strand and substrate oligonucleotides with Watson-Crick 
complementary sequences. FIG. 4C shows chemical ligation 
used to join the backbones of substrate oligonucleotides 
50 aligned along the template strand to extend the primer the 
full length of the template strand. FIG. 4D shows the 
intercalator and unused substrate oligonucleotides can be 
removed from the reaction mixture as an early step in the 
process of product strand purification. 
Another aspect provides a method of selecting a biopoly-
mer including the steps of generating a plurality of non-
natural biopolymers having a random sequence of mono-
mers flanked by predetermined sequences of monomers; 
selecting a subset of the plurality of the non-natural biopoly-
mers based on binding affinity to a target; and synthesizing 
natural biopolymers by intercalator-meditated template-di-
rected synthesis using the selected subset as templates. 55 FIGS. SA-B are a schematic representation of an exem-plary embodiment of intercalation-mediated synthesis that is 
restricted to the region between two primer oligonucle-
otides. FIG. SA shows two primer oligonucleotides are 
bound to a template strand (template strand is shown in 
Still another aspect provides a kit containing a template, 
biopolymer subunits, and an intercalator for performing 
intercalator-mediated template-directed synthesis. The kit 
optionally includes reagents, buffers, detectable labels, and 
instructions for performing the synthesis. 
BRIEF DESCRIPTION OF THE DRAWINGS 
60 gray). The "X's" on the outside ends of the two primers 
represent chemical modifications that prevent substrate liga-
tion to these ends. Substrate oligonucleotides are present 
which are necessary for the synthesis of the product strand 
FIG. lA is a diagram of the molecular structure of two 65 
base pairs from a high resolution structure of a B-form DNA 
double helix. 
between the two primers. The substrate oligonucleotides are 
sufficiently short that there is no appreciable equilibrium of 
substrate oligonucleotides bound to the template strand. 
FIG. SB shows the introduction of the intercalator molecule 
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and reagents for backbone coupling results in the formation 
of a product strand that connects the two primers. 
FIG. 6 is a schematic representation of an exemplary 
embodiment of a chemical procedure in which intercalation-
mediated template-directed synthesis is used to selectively 
amplify nucleic acids with non-natural backbones that have 
sequences that exhibit a desired chemical or biological 
activity. 
FIG. 7 A is an autoradiography image of a polyacryalmide 
gel run with a number of intercalation-mediated ligation 10 
experiments using 3'-phosphorothioate-( dT)3 and 5'-iodo-
( dT)4 as substrates, the DNA template (dA) 16, and the small 
molecule proflavine as an intercalator. 
8 
single or multiple stranded configurations, where one or 
more of the strands may or may not be completely aligned 
with another. A "nucleotide" refers to a subunit of a nucleic 
acid and has a phosphate group, a 5 carbon sugar and a 
nitrogen containing base, as well as functional analogs 
(whether synthetic or naturally occurring) of such sub-units 
which in the polymer form (as a polynucleotide) can hybrid-
ize with naturally occurring polynucleotides in a sequence 
specific manner analogous to that of two naturally occurring 
polynucleotides. Biopolymers include DNA (including 
cDNA), RNA, oligonucleotides, and PNA and other poly-
nucleotides as described in U.S. Pat. No. 5,948,902 and 
references cited therein (all of which are also incorporated 
herein by reference), regardless of the source. A "biomono-FIG. 7B is a line graph showing (dT)7 product yield as a 
function of proflavine concentration. 
FIG. 8 is a plot of (dT)7 product yield as a function of 
proflavine concentration for intercalation-mediated ligation 
experiments using 3'-phosphorothioate-(dT)3 and 5' iodo-
(dT)4 as substrates, the RNA template (rA) 16 , and proflavine 
as the intercalator. 
15 mer" references a single unit, which can be linked with the 
same or other biomonomers to form a biopolymer (e.g., a 
single amino acid or nucleotide with two linking groups one 
or both of which may have removable protecting groups). 
The term "fluid" means a material continuum that is 
20 unable to withstand a static shear stress. Unlike an elastic 
FIG. 9 is a diagram of the molecular structures of repre-
sentative intercalators. 
FIG. 10 is a plot of (dT)7 product yield as a function of 
proflavine concentration for intercalation-mediated ligation 
experiments using 3'-phosphorothioate-(dT)3 and 5' iodo- 25 
(dT)4 as substrates, the non-natural RNA template 2'-0-
methyl-(rA)7, and proflavine as the intercalator. 
FIG. llA is the chemical structure of a Watson-Crick 
A•T•T base triplet. 
FIG. llB is a diagram of the molecular structure of an 30 
exemplary intercalator, coralyne. 
FIG.12 is a schematic of intercalation-mediated template-
directed synthesis showing a duplex template strand in 
solution with substrate strands and the intercalator, coralyne. 
The addition of coralyne to the solution facilitated the 35 
formation ofHoogsteen base pairs between the purine bases 
of the template duplex and the pyrimidine bases of the 
substrate strands. 
FIG. 13 is an autoradiograph of a polyacryalmide gel run 
40 
with an intercalation-mediated ligation experiment using 
3'-phosphorothioate-( dT)
3 
and 5'-iodo-( dT)4 as substrates, a 
duplex template, and the small molecule coralyne as an 
intercalator. The three left gel lanes show ( dT)7 product for 
the reaction containing coralyne. The three right lanes are 
45 for the same reaction without coralyne. 
DETAILED DESCRIPTION 
solid which responds to a shear stress with a recoverable 
deformation, a fluid responds with an irrecoverable flow. 
Exemplary fluids include, but are not limited to, water, 
aqueous solutions, non-aqueous solutions, ionic salts, and 
other flowable material. 
The term "biopolymer subunit(s)" means a biomonomer 
or group of two or more linked biomonomers. Exemplary 
biomonomers include, but are not limited to, nucleotides or 
nucleosides, amino acids, oligonucleotides, and polypep-
tides. 
The term "nucleic acid subunit(s)" means a single nucle-
otide or nucleoside or a group of two or more nucleotides or 
nucleosides. 
As used herein, the term "polynucleotide" generally refers 
to any polyribonucleotide or polydeoxribonucleotide, which 
may be unmodified RNA or DNA or modified RNA or DNA. 
Thus, for instance, polynucleotides as used herein refers to, 
among others, single- and double-stranded DNA, DNA that 
is a mixture of single- and double-stranded regions, single-
and double-stranded RNA, and RNA that is mixture of 
single- and double-stranded regions, hybrid molecules com-
prising DNA and RNA that may be single-stranded or, more 
typically, double-stranded or a mixture of single- and 
double-stranded regions. The terms "nucleic acid," "nucleic 
acid sequence," or "oligonucleotide" also encompasses a 
polynucleotide as defined above. 
In addition, polynucleotide as used herein refers to triple-
stranded regions comprising RNA or DNA or both RNA and 
DNA. The strands in such regions may be from the same 
1. Definitions: 
A "biopolymer" is a polymer of one or more types of 
repeating units. Biopolymers are typically found in biologi-
cal systems and particularly include polysaccharides (such 
50 molecule or from different molecules. The regions may 
include all of one or more of the molecules, but more 
typically involve only a region of some of the molecules. 
One of the molecules of a triple-helical region often is an 
oligonucleotide. 
It will be appreciated that a great variety of modifications 
have been made to DNA and RNA that serve many useful 
purposes known to those of skill in the art. The term 
polynucleotide as it is employed herein embraces such 
chemically, enzymatically or metabolically modified forms 
as carbohydrates), peptides (which term is used to include 
polypeptides and proteins), glycans, proteoglycans, lipids, 55 
sphingolipids, known biologicals materials such as antibod-
ies, etc. and polynucleotides as well as their analogs such as 
those compounds composed of or containing amino acid 
analogs or non-amino acid groups, or nucleotide analogs or 
non-nucleotide groups. This includes polynucleotides in 
which the conventional backbone has been replaced with a 
non-naturally occurring or synthetic backbone, and nucleic 
acids (or synthetic or naturally occurring analogs) in which 
one or more of the conventional bases has been replaced 
with a group (natural or synthetic) capable of participating 
60 of polynucleotides, as well as the chemical forms of DNA 
and RNA characteristic of viruses and cells, including 
simple and complex cells, inter alia. 
in hydrogen bonding interactions, such as Watson-Crick 
type, Wobble type and the like. Polynucleotides include 
The term "oligonucleotide" refers to relatively short poly-
nucleotides. Typically the term refers to single-stranded 
65 deoxyribonucleotides, but it can refer as well to single- or 
double-stranded ribonucleotides, RNA.DNA hybrids and 
double-stranded DNAs, among other compounds containing 
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--O-N(CH3)-CH2-CH2- [wherein the native phos-
phodiester backbone is represented as --O-P-O-
CH2-] of the above referenced U.S. Pat. No. 5,489,677, 
and the amide backbones of the above referenced U.S. Pat. 
No. 5,602,240. 
In other embodiments, the disclosed methods and com-
positions may comprise modified oligonucleotides contain-
ing one or more substituted sugar moieties. Other modified 
oligonucleotides comprise one of the following at the 2' 
multiple nucleotides linked through phosphodiester bonds. 
The phosphodiester bonds are typically 5'-3' linkages 
between the deoxyribose or ribose sugars of adjacent nucle-
otides, which is the predominant mode of nucleotide cou-
pling in natural DNA or RNA, respectively. The nucleotides 5 
of an oligonucleotide can be the naturally occurring ribo-
nucleotides, rA, rC, rG and rU; deoxyribonucleotides, dA, 
dC, dG and dT; or other compounds in which the backbone 
and/or the base moieties differ from the standard nucleotides 
of DNA and RNA. 10 position: OH; F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, 
S- or N-alkynyl; or O-alkyl-0-alkyl, wherein the alkyl, 
alkenyl and alkynyl may be substituted or unsubstituted C1 
to C10 alkyl or C2 to C10 alkenyl and alkynyl. Particularly 
preferred are O[(CH2)n0lmCH3, O(CH2)nOCH3, O(CH2)n 
The term "non-natural" means not typically found in 
nature including those items modified by man. Non-natural 
includes chemically modified subunits such as nucleotides 
as well as biopolymers having non-natural linkages, back-
bones, or substitutions. 
The term "non-natural backbone" means a covalent 
chemical linkage that couples together two or more nucle-
otides in a manner that is not identical to the naturally-
occurring RNA or DNA phosphodiester backbones. Chemi-
cal deviations from the natural backbone can include, but are 
not limited to, chemical modification of a single site on the 
natural backbone or the replacement of a component of the 
backbone with a completely different chemical group. 
Methylation of the 02' site on the ribose sugar is an example 
of a chemical difference from the natural backbone that 
would constitute a non-natural backbone. Replacement of 
the ribose sugar with a hexose sugar and/or replacement of 
the phosphate group in DNA or RNA with a phosphorothio-
15 NH2, O(CH2)nCH3, O(CH2)nONH2, and O(CH2)nON 
[(CH2)nCH3b where n and mare from 1 to about 10. Other 
oligonucleotides comprise one of the following at the 2' 
position: C1 to C10 lower alkyl, substituted lower alkyl, 
alkenyl, alkynyl, alkaryl, aralkyl, 0-alkaryl or 0-aralkyl, 
20 SH, SCH3, OCN, Cl, Br, CN, CF3, OCF3, SOCH3, S02CH3, 
ON02, N02, N3, NH2, heterocycloalkyl, heterocycloalkaryl, 
aminoalkylamino, polyalkylamino, substituted silyl, an 
RNA cleaving group, a reporter group, an intercalator, a 
group for improving pharmacokinetic properties and other 
25 substituents having similar properties. Another modification 
includes 2'-methoxyethoxy (2'-0--CH2CH20CH3, also 
known as 2'-0- (2-methoxyethyl) or 2'-MOE) (Martin et al. 
(1995) Helv. Chim. Acta, , 78, 486-504) i.e., an alkoxy-
alkoxy group. A further preferred modification includes ate group are also examples of non-natural backbones. 
Exemplary modified oligonucleotide backbones include, for 
example, phosphorothioates, chiral phosphorothioates, 
phosphorodithioates, phosphotriesters, aminoalkylphospho-
triesters, methyl and other alkyl phosphonates including 
3'-alkylene phosphonates, 5'-alkylene phosphonates and 
chiral phosphonates, phosphinates, phosphoramidates 35 
including 3'-amino phosphoramidate and aminoalkylphos-
phoramidates, thionophosphoramidates, thionoalkylphos-
phonates, thionoalkylphosphotriesters, selenophosphates 
and boranophosphates having normal 3'-5' linkages, 2'-5' 
linked analogs of these, and those having inverted polarity 
wherein one or more intemucleotide linkages is a 3' to 3', 5' 
30 2'-dimethylaminooxyethoxy, i.e., a O(CH2)20N(CH3)2 
group, also known as 2'-DMAOE, and 2'-dimethylaminoet-
hoxyethoxy (also known in the art as 2'-0-dimethyl-amino-
ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-0-CH2-0-
CH2-N(CH3)2. 
Other modifications include 2'-methoxy (2'-0-CH3), 
2'-aminopropoxy (2'-0CH2CH2CH2NH2), 2'-allyl (2'CH2-
CH=CH2), 2'-0-allyl (2'-0-CH2-CH=CH2)and 
2'-fluoro (2'-F). The 2'-modification may be in the arabino 
(up) position or ribo (down) position. An exemplary 2'-ara-
to 5' or 2' to 2' linkage. Representative oligonucleotides 
having inverted polarity comprise a single 3' to 3' linkage at 
the 3'-most intemucleotide linkage i.e. a single inverted 
nucleoside residue which may be abasic (the nucleobase is 
missing or has a hydroxyl group in place thereof). 
40 bino modification is 2'-F. Similar modifications may also be 
made at other positions on the oligonucleotide, particularly 
the 3' position of the sugar on the 3' terminal nucleotide or 
in 2'-5' linked oligonucleotides and the 5' position of 5' 
terminal nucleotide. Oligonucleotides may also have sugar 
45 mimetics such as cyclobutyl moieties in place of the pento-
furanosyl sugar. 
A further modification includes Locked Nucleic Acids 
(LNAs) in which the 2'-hydroxyl group is linked to the 3' or 
4' carbon atom of the sugar ring thereby forming a bicyclic 
50 sugar moiety. The linkage is preferably a methelyne 
(-CH2-)n group bridging the 2' oxygen atom and the 4' 
carbon atom wherein n is 1 or 2. LNAs and preparation 
thereof are described in U.S. Pat. No. 6,268,490 and WO 
99/14226. 
Some oligonucleotide backbones do not include a phos-
phorus atom therein and have backbones that are formed by 
short chain alkyl or cycloalkyl internucleoside linkages, 
mixed heteroatom and alkyl or cycloalkyl intemucleoside 
linkages, or one or more short chain heteroatomic or het-
erocyclic internucleoside linkages. These include those hav-
ing morpholino linkages (formed in part from the sugar 
portion of a nucleoside); siloxane backbones; sulfide, sul-
foxide and sulfone backbones; formacetyl and thiofor- 55 
macetyl backbones; methylene formacetyl and thiofor-
macetyl backbones; riboacetyl backbones; alkene containing 
backbones; sulfamate backbones; methyleneimino and 
methylenehydrazino backbones; sulfonate and sulfonamide 
backbones; amide backbones; and others having mixed N, 60 
0, S and CH2 component parts. 
Some embodiments synthesize or use oligonucleotides 
with phosphorothioate backbones and oligonucleosides with 
heteroatom backbones, and in particular --CH2-NH-O-
CH2-, -CH2-N(CH3)-0--CH2- [known as a meth- 65 
ylene (methylimino) or MMI backbone], -CH2-0-N 
(CH3)--CH2-, --CH2-N(CH3)-N(CH3)-CH2- and 
Oligonucleotides may also include nucleobase (often 
referred to in the art simply as "base") modifications or 
substitutions. As used herein, "unmodified" or "natural" 
nucleobases include the purine bases adenine (A) and gua-
nine (G), and the pyrimidine bases thymine (T), cytosine (C) 
and uracil (U). Modified nucleobases include other synthetic 
and natural nucleobases such as 5-methylcytosine (5-me-C), 
5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-ami-
noadenine, 6-methyl and other alkyl derivatives of adenine 
and guanine, 2-propyl and other alkyl derivatives of adenine 
and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 
5-halouracil and cytosine, 5-propynyl uracil and cytosine 
and other alkynyl derivatives of pyrimidine bases, 6-azo 
US 7,368,560 B2 
11 
uracil, cytosine and thymine, 5-uracil (pseudouracil), 
4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hy-
droxyl and other 8-substituted adenines and guanines, 5-halo 
particularly 5-bromo, 5-trifluoromethyl and other 5-substi-
tuted uracils and cytosines, 7-methylguanine and 7-methy- 5 
!adenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 
8-azaadenine, 7-deazaguanine and 7-deazaadenine and 
3-deazaguanine and 3-deazaadenine. Further modified 
nucleobases include tricyclic pyrimidines such as phenox-
azine cytidine(1H-pyrimido[5,4-b ][1,4]benzoxazin-2(3H)- 10 
one), phenothiazine cytidine (1H-pyrimido[5,4-b ][ 1,4]ben-
zothiazin-2(3H)-one ), G-clamps such as a substituted 
phenoxazine cytidine (e.g., 9-(2-aminoethoxy )-H-pyrimido 
[5,4-b ][1,4]benzoxazin-2(3H)-one ), carbazole cytidine (2H-
pyrimido[ 4,5-b ]indol-2-one ), pyridoindole cytidine (H-py- 15 
rido[3 ',2' :4, 5]pyrrolo [2,3-d]pyrimidin-2-one ). Modified 
nucleobases may also include those in which the purine or 
pyrimidine base is replaced with other heterocycles, for 
example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyri-
dine and 2-pyridone. Further nucleobases include those 20 
disclosed in U.S. Pat. No. 3,687,808, those disclosed in The 
Concise Encyclopedia of Polymer Science and Engineering, 
pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 
1990, those disclosed by Englisch et al., Angewandte Che-
mie, International Edition, 1991, 30, 613, and those dis- 25 
closed by Sanghvi, Y. S., Chapter 15, Antisense Research 
and Applications, pages 289-302, Crooke, S. T. and Lebleu, 
B., ed., CRC Press, 1993. Certain of these nucleobases may 
12 
The term "template-directed synthesis" in reference to 
biopolymer production, for example oligonucleotide pro-
duction, refers to the assembly of substrate molecules on an 
existing template strand through non-covalent interactions 
which results in the product strand, upon covalent coupling 
of the substrates, having a sequence, for example a nucle-
otide sequence, that is governed by the template strand. 
The term "intercalator-meditated template-directed syn-
thesis" means using an intercalator to facilitate interactions 
between a monomer or substrate strand and a template, for 
example sequence specific interactions, during template-
directed synthesis of a polymer. The intercalator can serve as 
a catalyst to promote sequence specific interaction between 
the template and the monomer. 
Fluorophores are compounds or molecules that lumi-
nesce. Typically fluorophores absorb electromagnetic 
energy at one wavelength and emit electromagnetic energy 
at a second wavelength. Representative fluorophores 
include, but are not limited to, 1,5 IAEDANS; 1,8-ANS; 
4-Methylumbelliferone; 5-carboxy-2, 7-dichlorofluorescein; 
5-Carboxyfluorescein ( 5-F AM); 5-Carboxynapthofluores-
cein; 5-Carboxytetramethylrhodamine (5-TAMRA); 5-FAM 
(5-Carboxyfluorescein); 5-HAT (Hydroxy Tryptamine); 
5-Hydroxy Tryptamine (HAT); 5-ROX (carboxy-X-
rhodamine ); 5-TAMRA ( 5-Carboxytetramethy lrhodamine); 
6-Carboxyrhodamine 6G; 6-CR 6G; 6-JOE; 7-Amino-4-
methylcoumarin; 7-Aminoactinomycin D (7-AAD); 7-Hy-
droxy-4-methylcoumarin; 9-Amino-6-chloro-2-methoxy-
acridine; ABQ; Acid Fuchsin; ACMA (9-Amino-6-chloro-
2-methoxyacridine ); Acri dine Orange; Acridine Red; 
Acridine Yellow; Acriflavin; Acriflavin Feulgen SITSA; 
Aequorin (Photoprotein); AFPs-AutoF!uorescent Pro-
tein-(Quantum Biotechnologies) see sgGFP, sgBFP; Alexa 
Fluor 350™; Alexa Fluor 430™; Alexa Fluor 488™; Alexa 
Fluor 532™; Alexa Fluor 546™; Alexa Fluor 568™; Alexa 
Fluor 594™; Alexa Fluor 633™; Alexa Fluor 647™; Alexa 
Fluor 660™; Alexa Fluor 680™; Alizarin Complexon; 
Alizarin Red; Allophycocyanin (APC); AMC, AMCA-S; 
AMCA (Aminomethylcoumarin); AMCA-X; Aminoactino-
be particularly useful for increasing the binding affinity of 
the oligomeric compounds of the disclosure. These include 30 
5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 
and 0-6 substituted purines, including 2-aminopropylad-
enine, 5-propynyluracil and 5-propynylcytosine. 5-methyl-
cytosine substitutions have been shown to increase nucleic 
acid duplex stability by 0.6-1.2.degree. C. (Sanghvi, Y. S., 35 
Crooke, S. T. and Lebleu, B., eds., Antisense Research and 
Applications, CRC Press, Boca Raton, 1993, pp. 276-278) 
and are presently preferred base substitutions, even more 
particularly when combined with 2'-0-methoxyethyl sugar 
modifications. 40 mycin D; Aminocoumarin; Aminomethylcoumarin 
The term "substrate strand" (or substrate oligonucleotide) 
an oligonucleotide, with either a natural or non-natural 
backbone, of two nucleotide units or greater that is coupled 
(AMCA); Anilin Blue; Anthrocyl stearate; APC (Allophy-
cocyanin); APC-Cy7; APTRA-BTC; APTS; Astrazon Bril-
liant Red 4G; Astrazon Orange R; Astrazon Red 6B; Astra-
zon Yellow 7 GLL; Atabrine; ATTO-TAG™ CBQCA; to another substrate strand or mononucleotide during a 
template-directed synthesis reaction. 
The term "template strand" means an oligonucleotide, 
with either a natural or non-natural backbone, that, by virtue 
of its nucleotide base sequence, guides the order of mono-
nucleotide bases or substrate strands that are covalently 
45 ATTO-TAG™ FQ; Auramine; Aurophosphine G; Aurophos-
phine; BAO 9 (Bisaminophenyloxadiazole); BCECF (high 
pH); BCECF (low pH); Berberine Sulphate; Beta Lacta-
mase; BFP blue shifted GFP (Y66H); Blue Fluorescent 
coupled as part of a template-directed synthesis reaction. 50 
The term "product strand" means an oligonucleotide, with 
either a natural or non-natural backbone, that is the product 
of a reaction in which shorter oligonucleotides or mono-
nucleotides are covalently coupled to form a longer oligo-
nucleotide with a nucleotide sequence that is determined by 55 
the template strand. 
Protein; BFP/GFP FRET; Bimane; Bisbenzamide; Bisben-
zimide (Hoechst); bis-BTC; Blancophor FFG; Blancophor 
SV; BOB0™-1; BOB0™-3; Bodipy 492/515; Bodipy 493/ 
503; Bodipy 500/510; Bodipy 505/515; Bodipy 530/10; 
Bodipy 542/563; Bodipy 18/568; Bodipy 564/517; Bodipy 
576/589; Bodipy 581/591; Bodipy 630/650-X; Bodipy 650/ 
665-X; Bodipy 665/676; Bodipy FI; Bodipy FL ATP; 
Bodipy FI-Ceramide; Bodipy R6G SE; Bodipy TMR; 
Bodipy TMR-X conjugate; Bodipy TMR-X, SE; Bodipy 
TR; Bodipy TR ATP; Bodipy TR-X SE; BO-PR0™-1; 
BO-PR0™-3; Brilliant Sulphoflavin FF; BTC; BTC-5N; 
The term "intercalator" means a molecule with a planar 
component that inserts entirely, or partially, between adja-
cent monomers or a polymer, for example nucleotide bases 
of a nucleic acid structure. 
The term "naturally-derived" when used in reference to a 
polymerase or a ligase enzyme indicates that the enzyme has 
60 Calcein; Calcein Blue; Calcium Crimson™; Calcium Green; 
Calcium Green-1 Ca2+ Dye; Calcium Green-2 Ca2 +; Cal-
cium Green-SN Ca2+; Calcium Green-C18 Ca2+; Calcium 
Orange; Calcofluor White; Carboxy-X-rhodamine (5-ROX); an amino acid sequence that was originally isolated from a 
living organism. An enzyme is still considered to be natu-
rally-derived if its amino acid sequence was subsequently 65 
mutated, evolved or truncated from the original naturally-
occurring sequence. 
Cascade Blue™; Cascade Yellow; Catecholamine; CCF2 
(GeneBlazer); CFDA; CFP--Cyan Fluorescent Protein; 
CFPNFP FRET; Chlorophyll; Chromomycin A; Chromo-
mycin A; CL-NERF; CMFDA; Coelenterazine; Coelentera-
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zine cp; Coelenterazine f; Coelenterazine fcp; Coelentera-
zine h; Coelenterazine hep; Coelenterazine ip; 
Coelenterazine n; Coelenterazine O; Coumarin Phalloidin; 
C-phycocyanine; CPM Methylcoumarin; CTC; CTC For-
mazan; Cy2™; Cy3.1 8; Cy3.5™; Cy3™; Cy5.1 8; 5 
Cy5.5™; Cy5™; Cy7™; Cyan GFP; cyclic AMP Fluorosen-
sor (FiCRhR); Dabcyl; Dansyl; Dansyl Amine; Dansyl 
Cadaverine; Dansyl Chloride; Dansyl DHPE; Dansyl fluo-
ride; DAPI; Dapoxyl; Dapoxyl 2; Dapoxyl 3' DCFDA; 
DCFH (Dichlorodihydrofluorescein Diacetate); DDAO; 10 
DHR (Dihydorhodamine 123); Di-4-ANEPPS; Di-8-
ANEPPS (non-ratio); DiA (4-Di-16-ASP); Dichlorodihy-
drofluorescein Diacetate (DCFH); DiD-Lipophilic Tracer; 
DiD (DiIC18(5)); DIDS; Dihydorhodamine 123 (DHR); Di! 
(Di!C18(3)); Dinitrophenol; DiO (DiOC18(3)); DiR; DiR 15 
(DiIC18(7)); DM-NERF (high pH); DNP; Dopamine; 
DsRed; DTAF; DY-630-NHS; DY-635-NHS; EBFP; ECFP; 
EGFP; ELF 97; Eosin; Erythrosin; Erythrosin ITC; 
Ethidium Bromide; Ethidium homodimer-1 (EthD-1); 
Euchrysin; EukoLight; Europium (III) chloride; EYFP; Fast 20 
Blue; FDA; Feulgen (Pararosaniline); FIF (Formaldehyd 
Induced Fluorescence); FITC; Flazo Orange; Fluo-3; Fluo-
4; Fluorescein (FITC); Fluorescein Diacetate; Fluoro-Em-
erald; Fluoro-Gold (Hydroxystilbamidine ); Fluor-Ruby; 
FluorX; FM 1-43™; FM 4-46; Pura Red™ (high pH); Pura 25 
Red™/Fluo-3; Fura-2; Fura-2/BCECF; Genacryl Brilliant 
Red B; Genacryl Brilliant Yellow 1 OGF; Genacryl Pink 3G; 
Genacryl Yellow 5GF; GeneBlazer (CCF2); GFP (S65T); 
GFP red shifted (rsGFP); GFP wild type, non-UV excitation 
(wtGFP); GFP wild type, UV excitation (wtGFP); GFPuv; 30 
Gloxalic Acid; Granular blue; Haematoporphyrin; Hoechst 
33258; Hoechst 33342; Hoechst 34580; HPTS; Hydroxy-
coumarin; Hydroxystilbamidine (FluoroGold); Hydrox-
ytryptamine; Indo-1, high calcium; Indo-1, low calcium; 
Indodicarbocyanine (DiD); Indotricarbocyanine (DiR); 35 
Intrawhite Cf; JC-1; JO-J0-1; JO-PR0-1; LaserPro; Lau-
rodan; LDS 751 (DNA); LDS 751 (RNA); Leucophor PAF; 
Leucophor SF; Leucophor WS; Lissamine Rhodamine; Lis-
samine Rhodamine B; Calcein/Ethidium homodimer; 
LOL0-1; LO-PR0-1; Lucifer Yellow; Lyso Tracker Blue; 40 
Lyso Tracker Blue-White; Lyso Tracker Green; Lyso 
Tracker Red; Lyso Tracker Yellow; LysoSensor Blue; 
LysoSensor Green; LysoSensor Yellow/Blue; Mag Green; 
Magdaia Red (Phloxin B); Mag-Pura Red; Mag-Fura-2; 
Mag-Fura-5; Mag-Indo-1; Magnesium Green; Magnesium 45 
Orange; Malachite Green; Marina Blue; Maxilon Brilliant 
Flavin 10 GFF; Maxilon Brilliant Flavin 8 GFF; Merocya-
nin; Methoxycoumarin; Mitotracker Green FM; Mitotracker 
Orange; Mitotracker Red; Mitramycin; Monobromobimane; 
Monobromobimane (mBBr-GSH); Monochlorobimane; 50 
MPS (Methyl Green Pyronine Stilbene); NBD; NBD 
Amine; Nile Red; Nitrobenzoxadidole; Noradrenaline; 
Nuclear Fast Red; Nuclear Yellow; Nylosan Brilliant lavin 
E8G; Oregon Green; Oregon Green 488-X; Oregon 
Green™; Oregon Green™ 488; Oregon Green™ 500; 55 
Oregon Green™ 514; Pacific Blue; Pararosaniline (Feul-
gen); PBFI; PE-Cy5; PE-Cy7; PerCP; PerCP-Cy5.5; PE-
TexasRed [Red 613]; Phloxin B (Magdaia Red); Phorwite 
AR; Phorwite BKL; Phorwite Rev; Phorwite RPA; Phos-
phine 3R; PhotoResist; Phycoerythrin B [PE]; Phycoeryth- 60 
rin R [PE]; PKH26 (Sigma); PKH67; PMIA; Pontochrome 
Blue Black; POP0-1; POP0-3; PO-PR0-1; PO-PR0-3; 
Primuline; Procion Yellow; Propidium Iodid (PI); PyMPO; 
Pyrene; Pyronine; Pyronine B; Pyrozal Brilliant Flavin 7GF; 
QSY 7; Quinacrine Mustard; Red 613 [PE-TexasRed]; 65 
Resorufin; RH 414; Rhod-2; Rhodamine; Rhodamine 110; 
Rhodamine 123; Rhodamine 5 GLD; Rhodamine 6G; 
14 
Rhodamine B; Rhodamine B 200; Rhodamine B extra; 
Rhodamine BB; Rhodamine BG; Rhodamine Green; 
Rhodamine Phallicidine; Rhodamine Phalloidine; 
Rhodamine Red; Rhodamine WT; Rose Bengal; R-phyco-
cyanine; R-phycoerythrin (PE); rsGFP; S65A; S65C; S65L; 
S65T; Sapphire GFP; SBFI; Serotonin; Sevron Brilliant Red 
2B; Sevron Brilliant Red 4G; Sevron Brilliant Red B; 
Sevron Orange; Sevron Yellow L; sgBFP™; sgBFP™ (su-
per glow BFP); sgGFP™; sgGFP™ (super glow GFP); 
SITS; SITS (Primuline); SITS (Stilbene Isothiosulphonic 
Acid); SNAFL calcein; SNAFL-1; SNAFL-2; SNARF cal-
cein; SNARF!; Sodium Green; SpectrumAqua; Spec-
trumGreen; SpectrumOrange; Spectrum Red; SPQ (6-meth-
oxy-N-(3-sulfopropyl)quinolinium); Stilbene; 
Sulphorhodamine B can C; Sulphorhodamine Extra; SYTO 
11; SYTO 12; SYTO 13; SYTO 14; SYTO 15; SYTO 16; 
SYTO 17; SYTO 18; SYT020; SYT021; SYT022; SYTO 
23; SYTO 24; SYTO 25; SYTO 40; SYTO 41; SYTO 42; 
SYTO 43; SYTO 44; SYTO 45; SYTO 59; SYTO 60; SYTO 
61; SYTO 62; SYTO 63; SYTO 64; SYTO 80; SYTO 81; 
SYTO 82; SYTO 83; SYTO 84; SYTO 85; SYTOX Blue; 
SYTOX Green; SYTOX Orange; Tetracycline; Tetrameth-
ylrhodamine (TRITC); Texas Red™; Texas Red-X™ con-
jugate; Thiadicarbocyanine (DiSC3); Thiazine Red R; Thia-
zole Orange; Thioflavin 5; Thioflavin S; Thioflavin TCN; 
Thiolyte; Thiozole Orange; Tinopol CBS (Calcofluor 
White); TMR; TO-PR0-1; TO-PR0-3; TO-PR0-5; TOT0-
1; TOT0-3; TriColor (PE-Cy5); TRITC Tetramethyl-
Rodaminelso ThioCyanate; True Blue; TruRed; Ultralite; 
Uranine B; Uvitex SFC; wt GFP; WW 781; X-Rhodamine; 
XRITC; Xylene Orange; Y66F; Y66H; Y66W; Yellow GFP; 
YFP; YO-PR0-1; YO-PR0-3; YOY0-1 ;YOY0-3 ,Sybr 
Green, Thiazole orange (interchelating dyes), semiconduc-
tor nanoparticles such as quantum dots, or caged fluorophore 
(which can be activated with light or other electromagnetic 
energy source) or a combination thereof. 
The terms "alk" or "alkyl" refer to straight or branched 
chain hydrocarbon groups having 1 to 12 carbon atoms, 
preferably 1 to 8 carbon atoms, such as methyl, ethyl, 
n-propyl, i-propyl, n-butyl, i-butyl, t-butyl, pentyl, hexyl, 
heptyl, octyl, etc. Lower alkyl groups, that is, alkyl groups 
of 1 to 6 carbon atoms, are generally most preferred. The 
term "substituted alkyl" refers to alkyl groups substituted 
with one or more groups, referably selected from aryl, 
substituted aryl, heterocyclo, substituted heterocyclo, car-
bocyclo, substituted carbocyclo, halo, hydroxy, alkoxy (op-
tionally substituted), aryloxy (optionally subsituted), alky-
lester (optionally substituted), arylester (optionally 
substituted), alkanoyl (optionally substituted), aryol (option-
ally substituted), cyano, nitro, amino, substituted amino, 
amido, lactam, urea, urethane, sulfonyl, etc. 
The term "alkenyl" refers to straight or branched chain 
hydrocarbon groups having 2 to 12 carbon atoms, preferably 
2 to 4 carbon atoms, and at least one double carbon to carbon 
bond (either cis or trans), such as ethenyl. The term "sub-
stituted alkenyl" refers to alkenyl groups substituted with 
one or more groups, preferably selected from aryl, substi-
tuted aryl, heterocyclo, substituted heterocyclo, carbocyclo, 
substituted carbocyclo, halo, hydroxy, alkoxy (optionally 
substituted), aryloxy (optionally substituted), alkylester (op-
tionally substituted), arylester (optionally substituted), 
alkanoyl (optionally substituted), aryol (optionally substi-
tuted), cyano, nitro, amino, substituted amino, amido, lac-
tam, urea, urethane, sulfonyl, etc. 
The term "alkynyl" refers to straight or branched chain 
hydrocarbon groups having 2 to 12 carbon atoms, preferably 
2 to 4 carbon atoms, and at least one triple carbon to carbon 
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bond, such as ethynyl. The term "substituted alkynyl" refers 
to alkynyl groups substituted with one or more groups, 
preferably selected from aryl, substituted aryl, heterocyclo, 
substituted heterocyclo, carbocyclo, substituted carbocyclo, 
halo, hydroxy, alkoxy (optionally substituted), aryloxy (op- 5 
tionally substituted), alkyl ester (optionally substituted), ary-
lester (optionally substituted), alkanoyl (optionally substi-
tuted), aryol (optionally substituted), cyano, nitro, amino, 
substituted amino, amido, lactam, urea, urethane, sulfonyl, 
16 
of the ring or ring system. The rings of multi-ring hetero-
cycles may be either fused, bridged and/or joined through 
one or more spiro unions. 
Exemplary monocyclic heterocyclic groups include aze-
tidinyl, pyrrolidinyl, pyrrolyl, pyrazolyl, oxetanyl, pyrazoli-
nyl, imidazolyl, imidazolinyl, imidazolidinyl, oxazolyl, 
oxazolidinyl, isoxazolinyl, isoxazolyl, thiazolyl, thiadiaz-
olyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, fury!, tet-
rahydrofuryl, thienyl, oxadiazolyl, piperidinyl, piperazinyl, 
etc. 
The terms "ar" or "aryl" refer to aromatic homocyclic 
(i.e., hydrocarbon) mono-, bi- or tricyclic ring-containing 
groups preferably having 6 to 12 members such as phenyl, 
naphthyl and biphenyl. Phenyl is a preferred aryl group. The 
term "substituted aryl" refers to aryl groups substituted with 
one or more groups, preferably selected from alkyl, substi-
tuted alkyl, alkenyl (optionally substituted), aryl (optionally 
substituted), heterocyclo (optionally substituted), halo, 
hydroxy, alkoxy (optionally substituted), aryloxy (optionally 
substituted), alkanoyl (optionally substituted), aroyl, (op-
tionally substituted), alkyl ester (optionally substituted), ary-
lester (optionally substituted), cyano, nitro, amino, substi-
tuted amino, amido, lactam, urea, urethane, sulfonyl, etc., 
where optionally one or more pair of substituents together 
with the atoms to which they are bonded form a 3 to 7 
member ring. 
10 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolodinyl, 
2-oxoazepinyl, azepinyl, 4-piperidonyl, pyridyl, pyrazinyl, 
pyrimidinyl, pyridazinyl, triazinyl, tetrahydropyranyl, tetra-
zoyl, triazolyl, morpholinyl, thiamorpholinyl, thiamorpholi-
nyl sulfoxide, thiamorpholinyl sulfone, 1,3-dioxolane and 
15 tetrahydro-1,1-dioxothienyl, and the like. 
Exemplary bicyclic heterocyclic groups include indolyl, 
benzothiazolyl, benzoxazolyl, benzothienyl, quinuclidinyl, 
quinolinyl, tetra-hydroisoquinolinyl, isoquinolinyl, benz-
imidazolyl, benzopyranyl, indolizinyl, benzofuryl, benzo-
20 furanly, dihydrobenzofuranyl, chromonyl, coumarinyl, ben-
zodioxolyl, dihydrobenzodioxolyl, benzodioxinyl, 
cinnolinyl, quinoxalinyl, indazolyl, pyrrolopyridyl, furopy-
ridinyl (such as furo[2,3-c ]pyridinyl, furo[3,2-b ]pyridinyl] 
or furo[2,3-b ]pyridinyl), dihydroisoindolyl, dihydro-
25 quinazolinyl (such as 3,4-dihydro-4-oxo-quinazolinyl), tet-
rahydroquinolinyl, azabicycloalkyls (such as 6-azabicyclo 
[3.2.l]octane), azaspiroalkyls (such as 1,4 dioxa-8-azaspiro 
[4.5]decane), imidazopyridinyl (such as imidazo[l,5-a] 
pyridin-3-yl), triazolopyridinyl (such as 1,2,4-triazolo[4,3-
The terms "cycloalkyl" and "cycloalkenyl" refer to 
mono-, bi- or tri homocylcic ring groups of 3 to 15 carbon 
atoms which are, respectively, fully saturated and partially 
unsaturated. The term "cycloalkenyl" includes bi- and tri-
cyclic ring systems that are not aromatic as a whole, but 
contain aromatic portions (e.g. fluorene, tetrahydronaptha-
lene, dihydroindene, and the like). The rings of multi-ring 
cycloalkyl groups may be either fused, bridged and/or joined 
through one or more spiro unions. The terms "substituted 35 
cycloalkyl" and "substituted cycloalkenyl" refer, respec-
tively, to cycloalkyl and cycloalkenyl groups substituted 
with one or more groups, preferably selected from aryl, 
substituted aryl, heterocyclo, substituted heterocyclo, car-
bocyclo, substituted carbocyclo, halo, hydroxy, alkoxy (op- 40 
tionally substituted), aryloxy (optionally substituted), alky-
lester (optionally substituted), arylester (optionally 
substituted), alkanoyl (optionally substituted), aryol (option-
ally substituted), cyano, nitro, amino, substituted amino, 
amido, lactam, urea, urethane, sulfonyl, etc. 
30 a ]pyridin-3-yl), and hexahydroimidazopyridinyl (such as 
1,5,6,7,8,8a-hexahydroimidazo[l ,5-a ]pyridin-3-yl), and the 
like. 
Exemplary tricyclic heterocyclic groups include carba-
zolyl, benzidolyl, phenanthrolinyl, acridinyl, phenanthridi-
nyl, xanthenyl and the like. 
The terms "substituted heterocycle", "substituted hetero-
cyclic", "substituted heterocyclic group" and "substituted 
heterocyclo" refer to heterocycle, heterocyclic and hetero-
cyclo groups substituted with one or more, preferably 
selected from alkyl, substituted alkyl, alkenyl, oxo, aryl, 
substituted aryl, heterocyclo, substituted heterocyclo, car-
bocyclo (optionally substituted), halo, hydroxy, alkoxy (op-
tionally substituted), aryloxy (optionally substituted), 
alkanoyl (optionally substituted), aroyl (optionally substi-
The terms "carbocyclo", "carbocyclic" or "carbocyclic 
group" refer to both cycloalkyl and cycloalkenyl groups. 
The terms "substituted carbocyclo", "substituted carbocy-
clic" or "substituted carbocyclic group" refer to carbocyclo 
45 tuted), alkylester (optionally substituted), arylester (option-
ally substituted), cyano, nitro, amido, amino, substituted 
amino, lactam, urea, urethane, sulfonyl, etc., where option-
ally one or more pair of substituents together with the atoms 
or carbocyclic groups substituted with one or more groups as 50 
described in the definition of cycloalkyl and cycloalkenyl. 
The terms "halogen" and "halo" refer to fluorine, chlo-
rine, bromine and iodine. 
The terms "heterocycle", "heterocyclic", "heterocyclic 
group" or "heterocyclo" refer to fully saturated or partially 55 
or completely unsaturated, including aromatic ("het-
eroaryl") or nonaromatic cyclic groups (for example, 3 to 13 
member monocyclic, 7 to 17 member bicyclic, or 10 to 20 
member tricyclic ring systems, preferably containing a total 
of 3 to 10 ring atoms) which have at least one heteroatom in 60 
at least one carbon atom-containing ring. Each ring of the 
heterocyclic group containing a heteroatom may have 1, 2, 
3 or 4 heteroatoms selected from nitrogen atoms, oxygen 
atoms and/or sulfur atoms, where the nitrogen and sulfur 
heteroatoms may optionally be oxidized and the nitrogen 65 
heteroatoms may optionally be quatemized. The heterocy-
clic group may be attached at any heteroatom or carbon atom 
to which they are bonded form a 3 to 7 member ring. 
The term "alkanoyl" refers to alkyl group (which may be 
optionally substituted as described above) linked to a car-
bonyl group (i.e. -C(O)-alkyl). Similarly, the term "aroyl" 
refers to an aryl group (which may be optionally substituted 
as described above) linked to a carbonyl group (i.e., -C(O)-
aryl). 
Throughout the specification, groups and substituents 
thereof may be chosen to provide stable moieties and 
compounds. 
The terms "including", "such as", "for example" and the 
like are intended to refer to exemplary embodiments and not 
to limit the scope of the present disclosure. 
2. Template-Directed Synthesis 
Certain embodiments of the disclosure provide composi-
tions and methods for coupling monomers or subunits, for 
example polynucleotides (substrate strands) or mononucle-
otides, into a polymer, for example a polynucleotide or a 
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longer oligonucleotide (product strand) in the presence or 
absence of an enzyme, for example a polymerase or ligase. 
10 
In one embodiment the sequence of the product strand is 
dictated by a preexisting polymer, for example a DNA or 
RNA oligonucleotide (template strand). Generally, interca-
lators, including but not limited to proflavine, are used to 
facilitate aligning monomers on the template strand, for 
example by aligning the monomers according to sequence 
specific complementarity on the template strand. In one 
embodiment, the associations of monomers with a template 
are more frequent in the presence of an intercalator than in 
the absence of an intercalator. In another embodiment, the 
duration and/or stability of the association of monomers 
with a template are increased in the presence of a intercalator 
compared to associations in the absence of the intercalator. 15 
Once aligned, the monomers are covalently coupled or 
ligated to each other using a number of enzyme-free chemi-
cal procedures or using an enzyme such as a polymerase or 
ligase. Representative chemical ligation procedures include 
but are not limited to 1) methods that require addition of a 20 
water soluble coupling agent, such as carbodimmide, 
cyanoimidazole, or K3Fe(CN)6, to a solution containing the 
monomers, for example nucleic acids, to be coupled (Fems 
et al., 1989; Kanaya and Yanagawa, 1986; Rubin et al., 
1995); 2) methods in which one of the two monomers, for 25 
example, nucleic acids to be coupled has a high-energy 
leaving group on a terminal phosphate, such as the methyl 
imidazole (Inoue and Orgel, 1982; Kanavarioti et al., 1998); 
3) and those methods in which the two monomers, for 
example, nucleic acids to be coupled are modified with 30 
different terminal groups that facilitate spontaneous covalent 
bond formation with each other, for example the use of a 
terminal phosphorothioate to form a covalent bond with an 
oligonucleotide that has an iodine or bromine atom to act as 
a leaving group during bond formation (Gryaznov et al., 35 
1994; Xu and Kool, 1999). In one embodiment, a nucleic 
acid strand produced by template-directed synthesis has a 
sequence that is the Watson-Crick complement of its tem-
plate strand. 
Another embodiment provides a method for template- 40 
directed synthesis of nucleic acids in a fluid, for example in 
aqueous solution. The method includes providing a template 
strand with nucleotide base sequence information of interest 
and substrates in the form of oligonucleotides or mononucle-
otides that can be covalently coupled to form a product 45 
strand with a sequence determined by the template strand. 
The oligonucleotides or mononucleotides are aligned on the 
template strand using an intercalator such that the bases of 
the substrates form Watson-Crick, or other (e.g., Hoogs-
teen), base pairs with the bases of the template strand. Once 50 
aligned, substrate nucleic acids are ligated using a chemical 
procedure for the formation of a covalent bond between the 
oligonucleotides or mononucleotides aligned on the tem-
plate strand. 
In living systems, polymerase and ligase enzymes play a 55 
critical role in promoting the alignment of substrate mono-
nucleotides and oligonucleotides, respectively, along tem-
plate strands. The Watson-Crick hydrogen bonds between 
nucleic acid substrates and templates provide only part of 
the free energy necessary for the assembly of a substrate- 60 
template helix; additional non-covalent interactions between 
the polymerase or ligase enzymes and the template-substrate 
complex provide additional stability and selectivity to 
ensure correct Watson-Crick base pairing. Natural poly-
merases and ligases have evolved to contain nanometer- 65 
scale cavities that match the shape of a nucleic acid duplex 
with Watson-Crick base pairs. Thus, the cavity provided by 
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polymerase and ligase enzymes is largely responsible for the 
fidelity in translation of sequence information from a tem-
plate strand to a product strand. These same protein enzymes 
also act as catalysts for promoting bond formation between 
oligonucleotides or mononucleotides that are assembled 
along a template strand. The energy necessary to promote 
formation of the phosphodiester bond in natural nucleic acid 
replication systems is provided in the form of nucleotide 
triphosphates (e.g. dATP, dGTP, dCTP, dTTP). 
Certain embodiments of the present disclosure provide 
compositions and methods to enable or improve the enzyme-
free template-directed synthesis of biopolymers, for 
example nucleic acid oligonucleotides and related polymers, 
in aqueous solution using molecules that intercalate the 
monomers of the biopolymer, for example that intercalate 
bases of nucleic acid structures (FIG. 1). More specifically, 
a particular molecule is used in a template-directed synthesis 
reaction that intercalates between the base pairs of a non-
covalent molecular assembly formed between a template 
strand and substrate oligonucleotides (FIG. 2). The non-
covalent assembly of substrate and template strands by the 
intercalator can increase the stability of the assembly and 
thereby enhance reaction yield (FIG. 2). A chemical or 
enzymatic method is used to couple the substrate oligonucle-
otides of the template-substrate-intercalator complex to 
yield the product strand (FIG. 2). The intercalator molecules 
can be added to the solution before the substrate oligonucle-
otides, after the substrate strands, or after the addition of 
both the template strands and substrate strands to the reac-
tion mixture. Molecules that interact with nucleic acid 
duplexes only through intercalation, as opposed to a com-
bination of intercalation and backbone interactions, make 
contacts only with the bases and only through non-covalent 
interactions. These interactions include dipole-dipole inter-
actions, dispersion interactions and interactions resulting 
from the hydrophobic effect. In a nucleic acid duplex, 
adjacent base pairs are stacked upon each other with a 
normal distance between the planes of the respective base 
pairs of 0.34 nm (FIG. 1). The insertion of an intercalator 
between two adjacent base pairs results in an increase in the 
normal distance between the planes of the intercalated base 
pairs from 0.34 nm to 0.68 nm (FIG. 1). The duplex structure 
accommodates this change in base pair separation by a local 
reduction in the twist of the helix. This increased separation 
of adjacent base pairs by untwisting of a duplex is possible 
because the distance between adjacent nucleotide bases 
along a nucleic acid backbone is approximately 0.68 nm. 
Chemical methods for the template-directed synthesis of 
nucleic acids promise to be far more amendable to use with 
non-natural nucleic acid backbones and base analogs than 
enzymatic methods. However, not using naturally-derived 
polymerase or ligase enzymes necessitates the use of an 
alternate means for promoting the formation of covalent 
bonds between substrate oligonucleotides, as well as an 
alternate means for promoting the non-covalent alignment of 
substrate oligonucleotides and/or mononucleotides on a 
template strand. Decades of research in the area of nucleic 
acid template-directed synthesis has demonstrated that 
hydrogen bonding between the nucleotide bases of a tem-
plate strand and substrate strands ofless than six nucleotides 
is insufficient for high yield and high sequence fidelity 
template-directed synthesis. The use of an intercalating 
molecule to promote the noncovalent assembly of substrate 
oligonucleotides along a template strand overcomes 
obstacles of prior enzyme-free methods for nucleic acid 
template-directed synthesis. 
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Certain embodiments of the present disclosure use inter-
calating molecules to enhance the assembly of substrate 
strands along a template strand, which will facilitate cova-
lent bond formation between substrates by any number of 
chemical methods. In one embodiment, the shape of the 5 
intercalator closely matches the shape of the Watson-Crick 
base pairs. In some embodiments, the intercalator need not 
make direct contact with any backbone atoms of the sub-
strate, template or product strands to promote template-
directed synthesis. Thus, one exemplary method of the 10 
present disclosure for improving template-directed synthesis 
is compatible with the natural backbone of nucleic acid 
polymers, but can also be used in template-directed synthe-
sis reactions that utilize oligonucleotides with non-natural 
backbones. Other embodiments of the present disclosure can 15 
be used to improve the template-directed synthesis of oli-
gonucleotides with a non-natural backbone on a natural 
nucleic acid template, the synthesis of oligonucleotides with 
natural backbones on a template with a non-natural back-
bone, or the synthesis of oligonucleotides with non-natural 20 
backbones on template strands with a non-natural backbone. 
3. Intercalators 
Exemplary intercalating molecules of the present disclo-
sure include, but are not limited to, compounds having a 25 
planar, generally aromatic, more particularly polycyclic 
moiety that inserts into a polymer, for example a nucleic 
acid. The intercalator can comprise of a planar, fused poly-
cyclic ring structure. A representative intercalator has the 
following structure: 30 
Formula! 
35 
20 
and G•C Watson-Crick base pairs are also shown in FIG. 3. 
A coplanar superimposition of the outline of the proflavine 
van der Waals surface on the Watson-Crick base pair models 
illustrates the excellent match between these three surfaces 
(FIG. 3). It has been long appreciated that the structure and 
van der Waals surface of the two Watson-Crick base pairs 
are very close. It is this structural similarity between the two 
Watson-Crick base pairs that allows the natural polymerases 
to recognize the correct base pairing during information 
transfer. Likewise, an intercalator with a molecular surface 
that matches one Watson-Crick base pair will also match the 
other base pair. The simple coplanar superposition of the 
proflavine surface on the A•T base pair surface reveals that 
approximately 90% of the Watson-Crick base pair surface is 
matched by the proflavine surface (FIG. 3). In the present 
disclosure, it is considered to be of substantial importance 
that the surface of the intercalator, used to promote template-
directed synthesis, closely match the surface of the base 
pairs to be formed between the bases of the template and 
substrate strands. 
Another embodiment provides an intercalator having the 
formula 
Formula II 
wherein each R1 is independently C, S, 0, or N; and 
R2 is independently H, OH, N, carboxy, carbonyl, car-
bocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
40 substituted heterocycle. 
wherein each R1 is independently C, S, 0, or N; 
R2 is independently H, OH, N, carboxy, carbonyl, car-
bocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 45 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle, 
R3 and R4 are independently C, S, 0, or N; 50 
R5 and R6 are independently H, OH, N, carboxy, carbonyl, 
carbocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 55 
substituted heterocycle. 
It will be appreciated that the compounds of the described 
formula can have one or more double bonds as shown or can 
be completely saturated. Further, one of skill in the art will 
recognize that each R1 can be substituted with R2 as shown. 60 
It will be appreciated that the compounds of the described 
formula can have one or more double bonds as shown or can 
be completely saturated. Further, one of skill in the art will 
recognize that each R1 can be substituted with R2 as shown. 
Still another embodiment provides an intercalator having 
of the formula: 
Formula III 
wherein R2 is independently H, OH, N, carboxy, carbonyl, 
carbocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle. 
A representative intercalator of formula I includes, but is 
not limited to proflavine (also known as 3,6,-diamino-
acrydine) or derivatives thereof. A van der Waals space-fill 
model of proflavine is shown in FIG. 3. The two-dimen-
sional projection of this model for proflavine defines a 
surface that is a reasonable approximation of the van der 
Waals surface of proflavine. Space-filling models of the A •T 
It will be appreciated that the compounds of the described 
formula can have one or more double bonds as shown or can 
65 be completely saturated. Further, one of skill in the art will 
recognize that each ring carbon can be substituted with R2 
as shown. 
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Another embodiment provides an intercalator having of 
the formula: 
22 
modifications at the ends of the oligonucleotide substrates 
are then responsible for creating a covalent bond to produce 
the product strand (FIG. 2). As an example of this particular 
Formula!V 5 
embodiment of the disclosure, the chemistry used to 
covalently couple substrate strands can be the 51 -iodine/3'-
phosphorothioate chemistry developed by Kool and cowork-
wherein R1 is independently H, OH, N, carboxy, carbonyl, 
carbocyclo, substituted carbocyclo, cycloalkyl, substituted 
cycloalkyl, alkyl, substituted alkyl, aryl, substituted aryl, 
pyridine, pyrole, furan, alkyl substituted pyridine, alkyl 
substituted pyrole, alkyl substituted furan, heterocycle, or 
substituted heterocycle. 
It will be appreciated that the compounds of the described 
formula can have one or more double bonds as shown or can 
be completely saturated. 
Amsacrine, 9-Aminoacridine-4-carboxamide, Daunomy-
cin, triostine A and echinomycin, acridine orange, 9-amino 
acridine, ethidium, ellipticine, actinomycin, and DAPI are 
additional suitable intercalators. 
The disclosed intercalators or derivatives thereof, are 
typically present in a ligation reaction in amounts ranging 
from about 1 nM to about 1 mM, about 100 nM to about 170 
µM, typically from about 500 nM to about 500 µM, and 
more typically from about 1 µM to about 300 µM, even more 
typically from about 10 to 200 µM. Specific concentrations 
of intercalator in a given ligation reaction may vary depend-
ing on ligation conditions such as ionic strength, tempera-
ture, and the concentration of template and subunits to be 
ligated. Generally, the concentration of template strand to 
intercalator is greater than 1: 1, and can be in the range of 1: 1 
to about 1:500, more typically about 1:200. 
4. Ligation Chemistry 
Embodiments of the present disclosure encompass a vari-
ety ofligation chemistries. For example, in one embodiment 
substrate monomers, for example mononucleotides, to be 
ligated are prepared with a methyl-imidazole-activated 
phosphate on the 5' position of ribose. The preparation of 
methyl-imidazole-activated mononucleotides has been 
described previously (Lohraian and Orgel, 1978 which is 
incorporated by reference herein in its entirety). A backbone 
linkage will form spontaneously when the methyl-imida-
zole-activated end of a substrate is brought into close 
proximity to an unmodified end of another substrate oligo-
nucleotide with the aid of intercalators and a template strand. 
This particular embodiment of the disclosure will be useful 
for applications that require the template-directed synthesis 
of oligonucleotides that contain only natural phosphodiester 
linkages, as the methyl-imidazole modification acts as a 
high-energy leaving group that promotes a natural phos-
phodiester bond formation between the terminal phosphate 
of a mononucleotide and the 3'-terminal OH group of an 
oligonucleotide. 
In another embodiment of the disclosure, chemical modi-
fications to the termini of oligonucleotide substrates are 
made, prior to the template-directed synthesis reaction that 
will promote the formation of a covalent bond between two 
oligonucleotides (FIG. 2). In the presence of a template 
strand, the intercalator greatly increases the equilibrium 
amount of the non-covalent assembly between the template 
strand and the substrate strands (FIG. 2). The chemical 
ers (Xu and Kool, 1999). In this chemical ligation procedure, 
one substrate oligonucleotide is prepared with an iodine 
atom substituted for a hydrogen atom on the 5' position of 
10 the 5'-terminal deoxyribose sugar. A second substrate oligo-
nucleotide is prepared with a phosphorothioate group on the 
3' position of the 3'-terminal deoxyribose sugar. The assem-
bly of two substrates such that the 3'-nucleotide of a phos-
phorothioate-modified oligonucleotide is in close proximity 
15 to the 5'-nucleotide of iodine-modified oligonucleotide leads 
to formation of a phosphorothioate backbone linkage that is 
analogous to the natural phosphodiester linkage. One skilled 
in the art of nucleic acid technology can prepare the oligo-
nucleotide template and substrate strands required for this 
20 reaction using an automated DNA synthesizer and commer-
cially available reagents. A protocol can be followed that is 
identical or similar to that reported previously by Kool and 
coworkers (Xu and Kool, 1999), with the additional step of 
an intercalator being added to the reaction mixture to 
25 enhance the stability of the template-substrate reaction com-
plex. 
The progress of an intercalator-enhanced template-di-
rected reaction can be followed using a number of tech-
niques familiar to those skilled in the art. For example, a 
30 portion of a reaction can be subjected to polyacrylamide gel 
electrophoresis (PAGE) under conditions that denature 
nucleic acid secondary structures (Beaucage et al., 2000). 
Nucleic acid molecules subject to electrophoresis in a poly-
acrylamide gel under denaturing conditions move through 
35 the gel matrix at rates that depend upon the length of the 
nucleic acid strand. Thus, knowledge of the substrate, tem-
plate and expected product oligonucleotide lengths will 
allow one skilled in the art to identify nucleic acid bands in 
a denaturing polyacrylamide gel that correspond to the 
40 substrate, product and template oligonucleotides. Changes 
in the amount of oligonucleotide in particular bands, both in 
the appearance of new bands and the change in the intensity 
of existing bands, can be used to follow the consumption of 
substrates and the formation of product strands. To visualize 
45 the oligonucleotides in a polyacrylamide gel, the gel can be 
stained with a dye (e.g. ethidium bromide) that allows 
detection of nucleic acids by UV excitation and fluorescence 
imaging (Beaucage et al, 2000). Alternatively, one or more 
of the substrate strands can be labeled with a radioactive 
50 phosphate group, such as 32P-phosphate, on a terminal end 
of an oligonucleotide that would not interfere with product 
formation during the ligation reaction (Beaucage et al., 
2000). When radioactive labeling is used as a detection 
method, DNA bands in a polyacrylamide gel are detected by 
55 either exposing X-ray film to the gel, or by the use of an 
imaging plate in which radioactive decay induces phospho-
rescence that can be imaged by a commercially available 
phosphorescence plate imager. 
In another embodiment of the disclosure, the reagents 
60 required to chemically ligate substrate oligonucleotides are 
not covalently bound to either of the substrates, but are 
added as separate reagents to the reaction mixture. The 
nucleic acid coupling chemistry that utilizes 1-(3-dimethy-
laminopropyl)-3-ethylcarbodiimide (GDI) for chemical acti-
65 vation of nucleic acid substrates (Shabarova et al., 1981; 
Shabarova et al., 1983; von Kiedrowski, 1986) serves as an 
example of this embodiment of the disclosure. For coupling 
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using GDI, the substrate oligonucleotides to be ligated are 
prepared with a phosphate group on the 5' end of one 
substrate and an OH group at the 3' end of the second 
substrate. The 5' phosphate can be added to the oligonucle-
otide using a standard enzymatic or chemical protocol 
(Beaucage et al., 2000). The substrate oligonucleotide on 
which the phosphate group is to be present is chosen such 
that when the two substrates are aligned on the template 
strand, the 5'-phosphate group of substrate will be adjacent 
to the 3'-end of the second substrate oligonucleotide. The 
assembly of these substrates on the template strand is 
facilitated by the addition of an intercalator. The coupling of 
substrates is achieved by the subsequent addition of GDI 
according to a published protocol (Shabarova et al., 1981; 
Shabarova et al., 1983; von Kiedrowski, 1986). 
the length of oligonucleotides required for template-directed 
synthesis from six to three bases in length, then only 64 
oligonucleotides will be necessary because there are only 64 
possible trinucleotide sequences ( 4 3=64 ). Thus, a two orders 
of magnitude reduction in oligonucleotide preparation could 
be achieved by the use of an intercalator that allows reduc-
tion in oligonucleotide length from six to three bases. This 
improvement greatly increases the potential utility of 
enzyme-free template-directed synthesis in which chemical 
10 ligation is used to couple oligonucleotides. 
In one embodiment of the disclosure, non-natural oligo-
nucleotides are used as template strands for the synthesis of 
natural DNA oligonucleotide product strands. For example, 
Depending upon the specific application, the ultimate use 
15 modified RNA oligonucleotides that have a methyl modifi-
cation on the 2'-oxygen of one or more ribose sugars of the 
oligonucleotide backbone can be used as template strands. 
The preparation of oligonucleotides with 2'-0-methyl modi-
of oligonucleotides prepared by the current disclosure may 
require separation of product strands from the intercalator. 
Separation of intercalators from oligonucleotides in a reac-
tion mixture is facilitated by the substantial difference 20 
between the molecular weight, size, and chemical properties 
of intercalators and oligonucleotides. Separation of oligo-
nucleotides and intercalators can be accomplished by several 
methods familiar to those skilled in the art, including, but not 
limited to: reverse-phase HPLC; cation-exchange chroma- 25 
tography, size exclusion chromatography and membrane 
dialysis. 
In one embodiment of the present disclosure, more than 
two oligonucleotides are assembled together, with the aid of 
intercalators, on a single template strand to allow the syn- 30 
thesis of a product strand that is the full length of the 
template strand (FIG. 2). In a particular application of this 
embodiment, the sequence of the template strand may not be 
known, in which case a set of oligonucleotides is added to 
the reaction mixture that, regardless of template sequence, 35 
contains a subset of oligonucleotides that can be ligated 
together to create any possible sequence that is the Watson-
Crick complement of the template strand. The chemical 
ligation method used for coupling the backbones of multiple 
intercalator-assembled oligonucleotides can be any of the 40 
chemical ligation methods known to those skilled in the art 
that proves compatible with nucleic acid intercalation. 
One advantage of the current disclosure is the length of 
oligonucleotides that can be ligated together along a tem-
plate strand is decreased substantially in comparison to 45 
existing methods for template-directed synthesis. This is 
important in regards to template-directed synthesis using 
multiple short oligonucleotides as substrates to produce a 
significantly longer product strand. The ability to use shorter 
oligonucleotides greatly reduces the number of substrate 50 
oligonucleotides necessary in a mixture that are required to 
insure generation of a product strand when using a template 
strand of unknown sequence. For example, if a nucleic acid 
polymer 120 bases in length is to serve as a template in an 
enzyme-free chemical ligation reaction in which an interca- 55 
lator is not used, the shortest oligonucleotide that can 
feasibly serve as substrates under typical reaction conditions 
and protocols are of approximately six nucleotides in length 
(Pritchard and Southern, 1997). This limit on oligonucle-
otide length comes about because oligonucleotides shorter 60 
than hexanucleotides do not bind with sufficient equilibrium 
to a template strand to allow appreciable product formation. 
The set of hexanucleotides required to insure the ability to 
produce all possible sequences of 120 nucleotides in length 
will require 4096 oligonucleotide substrates, which corre- 65 
sponds to the total number of possible hexanucleotide 
sequences ( 4 6=4096). If the use of an intercalator can reduce 
fications can be accomplished by one skilled in the art using 
an automated nucleic acid synthesizer and commercial 
reagents (Beaucage et al., 2000). The non-natural oligo-
nucleotide template is mixed in a reaction solution with 
intercalators and short oligonucleotide substrate strands that 
are chemically activated such that they spontaneously 
couple to form a full-length product strand when aligned 
along a template strand. By using this embodiment of the 
disclosure, the sequence information of a non-natural oli-
gonucleotide can be transferred to a natural oligonucleotide. 
In one embodiment of the disclosure, intercalation-medi-
ated template-directed synthesis can be used for primer 
extension. This process is analogous to the process by which 
naturally-derived polymerases copy a template strand into a 
product. In this embodiment of the disclosure, an oligo-
nucleotide with a specific sequence and length is bound to a 
complementary sequence site on a template strand (FIG. 4). 
The primer is of sufficient length that the equilibrium of 
binding is greatly favored at the reaction temperature. The 
oligonucleotide substrates that will serve as substrates for 
template-directed synthesis of the remaining length of the 
template strand are sufficiently short that the equilibrium 
concentration of two substrates bound at neighboring sites 
along the template strand is substantially smaller than the 
equilibrium concentration of substrate being bound next to 
the tightly-bound primer (FIG. 4). Both solution conditions, 
such as temperature and ionic strength, can be used in 
conjunction with intercalating molecules to create an equi-
librium situation where there is an appreciable equilibrium 
of oligonucleotides bound directly adjacent to the primer. 
Existing chemical ligation methods can then be used in 
conjunction with intercalation-enabled template-directed 
synthesis to extend the primer the full length of the template 
strand (FIG. 4). As a modification of this embodiment, a 
second primer can be bound at the opposite end of the 
template strand such that the process of intercalation-en-
abled template-directed synthesis produces a complete poly-
mer between the first and second primer (FIG. 5). This 
particular embodiment of the disclosure would be very 
useful for translating a series of template strands into 
product strands when the primer binding sites at the begin-
ning and end of the template strands are identical for all 
template strands, but the sequences between the two primer 
sites are highly variable. Furthermore, this embodiment of 
the disclosure would be useful when a limited region of a 
template strand is desired to be translated into a product 
strand. In which case, primers would be used to limit the 
extent of the template strand that is translated to the region 
between the two primers. This would be accomplished by 
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modifying the primers such that their ends that point outside 
the desired sequence are unable to be ligated to substrate 
oligonucleotides (FIG. 5). 
In other embodiments, the subunits of a polymer to be 
synthesized can be ligated in the presence of or using an 
enzyme, for example, a ligase or polymerase. The enzyme 
can be bacterial, eukaryotic including, but not limited to 
mammalian, or genetically modified versions thereof. Suit-
able polymerases include, but are not limited to, E. coli DNA 
10 polymerase I (holoenzyme ), E. coli large fragment of DNA 
polymerase I (Kienow fragment), Bateriophage T4 DNA 
polymerase, Bateriophage T7 DNA polymerase, modified 
Bacteriophage T7 DNA polymerase, reverse transcriptase, 
terminal transferase, and thermostable DNA polymerases 
15 
such as Taq polymerase. 
5. In vitro Selection 
26 
A technique such as HPLC or polyacrylamide gel elec-
trophoresis is used to separate the non-natural oligonucle-
otides from the DNA, resulting in non-natural oligonucle-
otides with an enrichment of sequences possessing the 
desired property (FIG. 6A). The non-natural oligonucle-
otides can then be subjected to the same selection procedure 
again. Repeating the entire cycle multiple times would allow 
the selection of molecules with non-natural backbones that 
have very specific properties. The selection criteria or con-
ditions can be modulated for example by eluting with a more 
shallow salt gradient and collection of only the oligonucle-
otides that come off the colunm at rather high salt condi-
tions. This will elute only the most powerful binding mol-
ecules. At the very end, the finally selected oligonucleotides 
are sequenced. It will be appreciated that non-natural oli-
gonucleotides can be purified from natural oligonucleotides 
by contacting a heterogeneous sample with enzymes that 
degrade natural DNA or RNA including, but not limited to, 
nucleases. 
The present disclosure will also be useful in facilitating 
the ligation of natural and non-natural nucleic acids that 
require ligation by chemical rather than enzymatic methods. 
Examples of when the present method may be useful, which 
are not meant to limit the scope of the disclosure, include 
Since the discovery that RNA molecules fold into three 
dimensional objects, which can have catalytic properties the 
selection of RNA and DNA molecules with specific molecu- 20 
lar recognition properties or catalytic capabilities has 
become a prime focus of research. These molecule are called 
ribozymes or DNAzymes. They can, like antibodies, bind 
specifically to small molecules and also larger proteins and 
they can bind to transition states and therefore stabilize 
them, which induces catalysis. DNAand RNA receptors able 
25 applications in which current methods suffer low product 
yield due to: 1) differences in the chemical structure of the 
template and/or product backbone from the natural nucleic 
acid backbone; 2) differences in the chemical structure of the 
bases from the natural bases; 3) changes in the gross 
to bind cellular proteins with high specificity are called 
aptamers. If they are used inside a cell to bind a specific 
protein in a cellular environment they are termed intramers. 
One process of finding these molecules is called SELEX 
standing for: systematic evolution of ligands by experimen-
tal enrichment. 
The ability of the present disclosure to enable synthesis of 
an oligonucleotide with a non-natural backbone using a 
template with a natural backbone provides a means to 
perform in vitro selection with non-natural oligonucleotides. 
In this embodiment of the disclosure, a sample of oligo-
nucleotides, for example RNA, DNA, or a combination 
thereof, with a non-natural backbone and a segment of 
random sequence are prepared (FIG. 6A). To this end an 
RNA or DNA oligonucleotide synthesizer is progranimed to 
couple not a single defined base but a mixture of all four 
bases. This randomized sequence is prepared in the middle 
30 morphology of the nucleic acids, as in the ligation of 
non-duplex structures, such as triplexes, quadruplexes and 
branched junctions. In a preferred embodiment of the dis-
closure, the molecules produced using the disclosure are 
biologically active and used for a therapeutic application, or 
35 have desired physical properties for use as new materials. 
Exemplary therapeutics include, but are not limited to, 
antisense oligonucleotides, siRNA, and oligonucleotides 
that bind to specific epitopes of a protein or biomolecule. 
40 6. Inhibitory Nucleic Acids 
to two defined sequences needed for primer recognition. A 45 
library having a mixture of 1015 -1016 individual oligonucle-
otide molecules is generally obtained. 
Other embodiments provide methods for producing 
inhibitory nucleic acids using intercalator-mediated tem-
plate-directed synthesis. Inhibitory nucleic acids include, 
but are not limited to RNA interference (RNAi) technology, 
anti-sense DNA, D-RNAi (Messenger RNA-antisense DNA 
Interference), catalytic nucleic acids, and Peptide Nucleic 
Acids (PNAs). Anti-sense nucleic acids can be described as 
oligonucleotides characterized by short, gene-specific 
sequences of nucleic acids. Classical antisense compounds 
50 target specific strands of RNA within the cell to bind with, 
thus preventing translation of that RNA and thereby reduc-
ing levels of the corresponding protein. 
The library can then be subjected to an activity or struc-
ture-based selection process that reduces the oligonucle-
otides to a subset that have a desired property (FIG. 6B). For 
example the library can be put onto an affinity column 
having a target molecule bound on a matrix. Suitable matri-
ces include, but are not limited to, a polymer or hydrophobic 
silica gel. Those individual oligonucleotides of the library 
which have some affinity to the colunm and most likely to 55 
the compound bound to the surface will be retarded. These 
molecules are then eluted for example by increasing the salt 
concentration of the eluent. Fractions of eluate are collected 
from the affinity colunm containing non-natural oligonucle-
otides of interest. 
This subset of non-natural biopolymers is then translated 
into DNA comprising natural nucleotides using intercala-
tion-enhanced template-directed synthesis (FIG. 6C) and the 
DNA is then amplified using PCR (Batlett and Stirling, 
2003) (FIG. 6D). The DNA is then translated back to the 
non-natural backbone by intercalation-enhanced template-
directed synthesis (FIG. 6E). 
6.1 RNA Interference (RNAi) 
One embodiment of the disclosure, provides methods and 
compositions for synthesizing molecules for use in the 
RNAi pathway which will enhance the efficiency of RNAi 
technology, thus providing new therapeutic modalities that 
target specific genes in their associated diseases. Generally, 
60 the template nucleic acid will correspond to a target RNA to 
be down regulated. A complementary strand of RNA can be 
synthesized using intercalator-mediated template-directed 
synthesis. In one embodiment, the template RNA is a 
non-natural RNA. In another embodiment, the template 
65 RNA is a natural RNA and the syntheses complementary 
RNA comprises a modified backbone or non-natural nucle-
otide, or a combination thereof. 
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siRNAs of the present disclosure can also be an effective 
therapeutic for neurodegenerative diseases caused by the 
overexpression of mutated genes or of proteins containing 
long polyglutamine stretches. The onset of neuronal cell 
death can be slowed or prevented by targeting the expression 
of the mutated allele or the polyglutamine sequence. 
To date, injection and transfection of dsRNA into cells 
and organisms has been the main method of delivery of 
siRNA. And while the silencing effect lasts for several days 
RNA interference (RNAi) silences gene expression in a 
sequence-specific manner by cleaving mRNAs containing 
short sequences that are closely homologous to a target 
sequence. Short double-stranded RNAs, known as small 
interfering RNAs (siRNA), are incorporated into an RNA-
induced silencing complex that directs degradation of RNA 
containing a homologous sequence. RNAi was originally 
described in plants and in Caenorhabditis elegans, and has 
since been described in fungi, worms, flies, and mammals. 
RNAi acts via the targeted degradation of mRNAs contain-
ing homologous (often identical) sequences to introduced 
short oligonucleotides. In organisms such as Drosophila and 
C. elegans, RNAi can be induced by introducing long 
dsRNA complementary to the target mRNA to be degraded. 
Transfection of long dsRNA molecules (>30 nt) into most 
mammalian cells causes nonspecific suppression of gene 
expression, as opposed to the gene-specific suppression seen 
10 and does appear to be transferred to daughter cells, it does 
eventually diminish. The present disclosure provides com-
positions and methods for synthesizing non-natural struc-
tural analogs of dsRNA and siRNA that are not susceptible 
to cellular enzymatic degradation, thus increasing the sus-
15 tainability within the cell. 
in other organisms. This suppression has been attributed to 
an antiviral response, which takes place through one of two 
pathways. To circumvent this, siRNAs are used to induce 20 
RNAi in mammalian cells and organisms. 
In some embodiments, long double-stranded RNAs (dsR-
NAs; typically >200 nt) can be used to silence the expression 
of target genes in a variety of organisms and cell types (e.g., 
mammals, worms, fruit flies, and plants). Upon introduction, 25 
the long dsRNAs enter a cellular pathway that is commonly 
referred to as the RNA interference (RNAi) pathway. First, 
the dsRNAs get processed into 20-25 nucleotide (nt) small 
interfering RNAs (siRNAs) by an RNase III-like enzyme 
called Dicer (initiation step) in an ATP-dependent, proces- 30 
sive manner. Then, the siRNAs assemble into endoribonu-
clease-containing complexes known as RNA-induced 
silencing complexes (RISCs ), unwinding in the process. The 
siRNA strands subsequently guide the RISCs to comple-
mentary RNA molecules, where they cleave and destroy the 35 
cognate RNA (effector step). Cleavage of cognate RNA 
takes place near the middle of the region bound by the 
siRNA strand. 
Other embodiments provide non-natural inhibitory 
nucleic acids synthesized by intercalator-mediated template- 40 
directed synthesis. There are several genes associated with 
cancer that are overexpressed to make cells resistant to 
native immunity, treatment, or normal senescence. Many of 
these genes are overexpressed in a wide array of tumors and 
are attractive candidates for RNAi silencing. The inhibitory 45 
nucleic acids of the present disclosure can be targeted to: the 
multidrug-resistance protein (MDR), which pumps chemo-
therapeutic drugs out of tumors; telomerase, which over-
comes the chromosomal shortening that occurs with each 
cell division; Bcl-2, which makes cell resistant to caspase- 50 
mediated apoptosis. Other potential targets for silencing 
include but are not limited to the following growth factors or 
growth factor receptors that have oncogenic roles in specific 
tumors: IL-6 for multiple myeloma; Her-2 for breast cancer; 
viral oncogenes such as the HPV genes E6 and E7 for 55 
cervical cancer. 
Viruses and other infectious agents may be targets of 
RNAi. These include but are not limited to influenza, severe 
acute respiratory syndrome, hepatitis B (HBV), hepatitis C 
(HCV), HIV, and intracellular pathogens (Mycobacterium 60 
tuberculosis). Certain bacteria are not typically amenable to 
RNAi silencing because of a lack of RNAi machinery, but 
the silencing of genes involved in the host immune response 
to life-threatening bacteria is possible. For example, reduc-
ing the expression of pro-inflammatory cytokines including, 65 
but not limited to, interleukin-I (IL-1 ), tumor necrosis factor 
a (TNFa), may lesson the risk of septic shock. 
6.2 Anti-sense DNA 
In another embodiment, the methods and compositions of 
the present disclosure can be used to generate molecules 
with anti-sense DNA properties. Antisense technology 
focuses on defeating diseases before the faulty proteins 
which cause them can even be formed. The production of 
these faulty proteins begins in the nucleus, with the DNA of 
the cell. In the nucleus the DNA forms pre-mRNA, which 
will leave the nucleus to enter the cytoplasm. In the cyto-
plasm this mRNA moves to a ribosome, where it is trans-
lated into amino acids. These amino acids are what make up 
the faulty proteins. Many traditional drugs target diseases by 
focusing on the faulty proteins themselves. Antisense goes a 
step further, by preventing the production of these incorrect 
proteins. The antisense DNA is inserted into the cell's 
cytoplasm. Next, the DNA of the nucleus codes the mRNA, 
which enters the cytoplasm of the cell. But instead of 
moving to a ribosome, this disease-producing mRNA con-
nects to the strand of antisense DNA. So instead of produc-
ing proteins, the faulty mRNA is negated by the oligonucle-
otide. The disclosed methods and compositions are useful in 
synthesizing specific oligonucleotides or antisense DNA. 
6.3 D-RNAi (MessengerRNA-antisense DNA Interference) 
Another embodiment of the present disclosure provides 
applications using D-RNAi as a defense process against 
various diseases. D-RNAi is a novel posttranscriptional 
phenomenon of silencing gene expression by transfection of 
mRNA-aDNAhybrids. It has been shown to have long-term 
gene knockout effects and thus has applications for treating 
diseases including, but not limited to cancer and viral 
infections. D-RNAi is a process that introduces hybrids of 
mRNA and antisense DNA into mammalian cells, resulting 
in the specific silencing of genes homologous to the deliv-
ered mRNA-aDNA hybrid (Lin, 2001 ). The antisense DNA 
can be produced using the disclosed methods to provide 
enzyme resistance and to increase the effectiveness of the 
antisense DNA. In vivo and In vitro experiments have 
demonstrated the gene silencing effect of the D-RNAi 
process. The D-RNAi mechanism has been implicated in the 
following experiments: the experimental demonstration of 
bcl-2 oncogene knockout in human prostate cancer LNCaP 
cells, the developmental retardation of liver lobe formation 
by silencing catenin genes in chicken embryos, and the 
interference of viral gene expressions in HIV-infected CD4+ 
T cells. 
6.4 Peptide Nucleic Acid (PNAs) 
Another embodiment provides methods of replicating 
PNAs using intercalator-mediated template-directed synthe-
sis. The structure of a peptide nucleic acid (PNA) is similar 
to a DNA oligomer except that there is no phosphodiester 
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backbone. PNAs are nucleic acid mimics that contain a 
pseudo-peptide backbone composed of charge neutral and 
achiral N-(2-aminoethyl) glycine units to which the nucleo-
bases are attached via a methylene carbonyl linker. PNAs 
bind DNA and RNA with high specificity and selectivity. 
The binding affinity and selectivity of PNAs for nucleic 
acids can be modified by the introduction of stereogenic 
centers (such as D-Lys-based units) into the PNA backbone. 
PNA monomers can be easily synthesized into oligomers as 
long as 20 bases using protocols for standard peptide syn-
thesis 
The methods of the present disclosure can be used in the 
synthesis of PNAs and associated complexes including, but 
not limited to, PNA-PNA, PNA-DNA, and PNA-RNA, and 
PNA2 -DNA. PNAs have proved to be useful molecules in 
DNA hybridization and antisense techniques. PNA com-
plexes with DNA and RNA tend to be more stable than the 
related DNA-DNA or DNA-RNA duplexes, which are also 
very stable. 
6.5 Targets for Anti-sense Therapeutics 
As noted above certain embodiments provide methods 
and compositions for the synthesis of antisense oligonucle-
otides which offer the possibility of specific, rational, 
genetic-based therapeutics. Human cancer therapy is of 
particular interest in this field of research. Examples of 
cancer targets include, but are not limited to, bcl-2, BCR-
ABL, C-raf-1, Ha-ras, c-myc, PKC, PKA, p53, and MDM2. 
Many genes specific to breast cancer that have been selected 
as targets for antisense therapy include, but are not limited 
to, HER-2/neu, PKA, TGF-A, EGFR, TGF-a, IGFIR, P12, 
MDM2, BRCA, Bcl-2, ER, VEGF, MDR, ferritin, transfer-
rin receptor, IRE, C-fos, HSP27, C-myc, C-raf and metal-
lothionein genes. 
7. Microarrays 
One embodiment provides a method of producing 
microarrays containing non-natural polynucleotides. For 
example, non-natural polynucleotides can be synthesized 
using the disclosed intercalator-mediated template-directed 
methods. The synthesized non-natural polynucleotides can 
be spotted onto a solid support to produce a microarray. 
Methods of fabricating microarrays are known in the art. In 
certain embodiments, the template is a non-natural poly-
nucleotide having a predetermined sequence complementary 
to a target nucleic acid. 
30 
The whole microarray process is based on hybridization 
probing, a technique that uses fluorescently labeled nucleic 
acid molecules as "mobile probes" to identify complemen-
tary molecules, sequences that are able to base-pair with one 
another. Base-pairing (i.e., A-T and G-C for DNA; A-U and 
G-C for RNA) or hybridization is the underlining principle 
of DNA microarray. An array is an orderly arrangement of 
samples. It provides a medium for matching known and 
unknown DNA samples based on base-pairing rules and 
10 automating the process of identifying the unknowns. An 
array experiment can make use of common assay systems 
such as microplates. In general, arrays are described as 
macroarrays or microarrays, the difference being the size of 
the sample spots. Macroarrays contain sample spot sizes of 
15 about 300 microns or larger and can be easily imaged by 
existing gel and blot scanners. The sample spot sizes in 
microarray are typically less than 200 microns in diameter 
and these arrays usually contains thousands of spots. 
DNA microarray, or DNA chips can be fabricated by 
20 high-speed robotics, generally on, but not limited to glass or 
nylon substrates, for which probes with known identity are 
used to determine complementary binding, thus allowing 
massively parallel gene expression and gene discovery stud-
ies. The introduction of solid supports could greatly increase 
25 the range of applications of the disclosed method in con-
junction with array-based methods. The supports could be, 
but are not limited to, glass microscope slides, silicon chips, 
or nylon membranes. An "array" can be defined as "to place 
in an orderly arrangement" or "an orderly arrangement." It 
30 is important that the gene sequences in a microarray are 
attached to their support in an orderly or fixed way, because 
researchers use the location of each spot in the array to 
identify a particular gene sequence. The spots themselves 
can be DNA, cDNA, or oligonucleotides. The present dis-
35 closure can be used to synthesize the specific "spots" as 
natural or non-natural DNA, cDNA, or oligonucleotides. 
Microarrays produced using the disclosed methods can be 
used to investigate gene expression changes in angiogenesis, 
schizophrenia, type I diabetes, breast cancer, leukemia, 
40 neurological tumors. Personalized drugs, molecular diag-
nostics, and integration of diagnosis and therapeutics are 
examples of the long-term potential for microarrays pro-
duced using the disclosed methods. 
45 8. Kits 
The disclosed microarrays use the ability of a given 
mRNA molecule to bind specifically to, or hybridize to, the 
DNA template from which it originated. By using an array 
containing many DNA or RNA samples, the expression 
levels of hundreds or thousands of genes within a cell can be 50 
detected by measuring the amount of mRNA bound to each 
site on the array. With the aid of a computer, the amount of 
mRNA bound to the spots on the microarray is precisely 
measured, generating a profile of gene expression in the cell. 
Other embodiments provide kits for performing template-
directed polymer synthesis. The kit typically includes mono-
mers, such as mono- or polynucleotides or amino acids and 
peptides. The monomers can be labeled with a detectable 
label. Detectable labels are known in the art an include, but 
are not limited to, biotin, strepavidin, radioisotopes, fluoro-
phores, phosphors, enzymes such as alkaline phosphatase, 
nanoparticles such as gold or silver particles of 100 nm or 
less in diameter, spin labels, molecular beacons, quenchers, 
and chromophores. The mono- or polynucleotide can be 
natural or non-natural. The polynucleotides typically include 
at least two natural or non-natural nucleotides. In one 
embodiment, the polynucleotides have a non-natural back-
bone. The kit also includes an intercalator as disclosed 
herein. Generally, the intercalator is a planar, polycyclic 
molecule, or a compound that contains a planar moiety 
capable of inserting between monomers of a polymer. The 
kit also contains ligation reagents. The ligation reagents 
include, but are not limited to, reagents for chemical ligation 
or enzymatic ligation as disclosed herein. Representative 
chemical ligation reagents include 1-(3-dimethylaminopro-
pyl)-3-ethylcarbodiimide (GDI). Enzymatic reagents 
There are two major application forms for the DNA 55 
microarray technology: 1) Identification of sequence (gene/ 
gene mutation) in which probe cDNA (500-5,000 bases 
long) is immobilized to a solid surface such as glass using 
robot spotting and exposed to a set of targets either sepa-
rately or in a mixture; and 2) Determination of expression 60 
level (abundance) of genes in which an array of oligonucle-
otide (20-80-mer oligos) or peptide nucleic acid (PNA) 
probes is synthesized either in situ (on-chip) or by conven-
tional synthesis followed by on-chip immobilization. The 
array is exposed to labeled sample DNA, hybridized, and the 65 
identity/abundance of complementary sequences are deter-
mined. 
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include polymerases, ligases, or combinations thereof. Buff-
ers, co-factors, chelators, detectable labels and other 
reagents can also be included. The kit can also contain 
instructions for synthesizing non-natural polynucleotides 
from natural templates or instructions for synthesizing natu-
ral polynucleotides from non-natural templates. 
EXAMPLES 
Example 1 
For example, the present disclosure could be used in an 
enzyme-free template-directed ligation reaction that would, 
10 
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diluting 3'-phosphorotioate-( dT)3 from a stock solution to 10 
µM strand in 100 µI ofT4 polynucleotide kinase buffer (New 
England Biolabs, Beverly, Mass.). 10 units of T4 polynucle-
otide kinase (New England Biolabs) were added to the 
buffered DNA solution. 3 µI y-32P-ATP (ICN, Costa Mesa, 
Calif.), 10 µCi/µ!, was then added to the solution. The kinase 
reaction mixture was allowed to incubate at 37 °C. for 30 
mm. 
Ligation Reactions 
Reactions were carried out in 100 µI volumes in a buffer 
containing 10 mM Tris buffer (pH 8.2); 10 mM NaCl; 100 
mM 2-mercaptoethanol. The substrate 5'-iodo-(dT)4 , the 
substrate 32P-labeled-3'-phosphorotioate-( dT)3 , and the tem-in the absence of an intercalator, yield too little product to be 
of any practical purpose. 
The utility of the present disclosure in a template-directed 
ligation reaction is demonstrated by measuring the amount 
of product strand that results from the coupling of the 
trinucleotide (dT)3 to the tetranucleotide (dT)4 on a (dA)16 
template in the presence and absence of the intercalator 
proflavine (FIG. 1). The product of this ligation reaction 
contains a single phosphorothioate linkage. Thus, the back-
bone of the product strand is not strictly DNA, like the 
template strand. However, the product strand backbone is an 
extremely close analog of DNA. 
15 plate (dA)16 were added to the reaction buffer to a final 
concentration for each of 1.0 µM in strand. The presence of 
2-mercaptoethanol in the reaction buffer prevented dimer-
ization of the 3'-phosphorothioate-(dT)3 substrate by reduc-
ing disulfide bond formation. To each of a series of identical 
20 reaction mixtures, the intercalator, proflavine, was added to 
final concentrations from 10 to 200 µM. The exact interca-
lator concentrations investigated are shown on FIG. 7. 
Ligation reactions were incubated for 24 h at 4 ° C. and then 
stopped by plunging reaction test tubes into liquid nitrogen 
25 and freeze-drying. 
Synthesis and Purification of Oligonucleotides. 
Substrate oligodeoxynucleotides were synthesized on a 
one micromole scale on an Expedite model 8909 synthesizer 
using standard phosphoramidite coupling chemistry. The 
30 3'-phosphorothioate-(dT)
3 
oligo synthesis was carried out on 
a 3'-phosphate controlled pore glass support (Glen Research, 
Sterling, Va.) where the oxidation reagent that would nor-
mally be added during the first nucleotide coupling cycle 
was replaced by a sulfurizing reagent (Glen Research). The 
remaining synthesis and deprotection steps were standard 35 
DNA nucleotide coupling cycles. The 5'-iodo-(dT)4 sub-
strate oligo was synthesized using the commercially avail-
able 5'-iodothymidine phosphoramidite reagent (Glen 
Research). Cleavage of iodine-containing strand from the 
CPG support was accomplished by incubation in concen- 40 
trated ammonium hydroxide for 2 hat room temperature. No 
further deprotection was required for the 5'-iodo-(dT)4 sub-
strate. Substrate oligonucleotides were purified by reverse 
phase HPLC on a C18, semi-preparative column. Template 
DNA, (dA) 16, was synthesized on the automated synthe- 45 
sizer, deprotected by incubation in ammonium hydroxide at 
1 ° C. for 18 h. Following evaporation of ammonium hydrox-
ide on a concentrating centrifuge, (dA)16 was purified from 
deprotecting groups and truncation products by passage over 
a 1 m G-15 column (Pharmacia). Stock solutions of DNA 50 
molecules were prepared by resuspending freeze-dried puri-
fied samples of each oligonucleotide in 1 ml of deionized 
HiO. The concentrations of DNA stock solutions were 
determined spectrophotometrically based upon sample 
absorption at 260 nm. 55 
Proflavine Stock Preparation 
Proflavine (hemisulfate salt) was purchased from Sigma. 
Stock solutions of 100 µM to 10 mM proflavine were 
prepared by dissolving solid proflavine sulfate in deionized 60 
H20. Concentrations of stock solutions were determined by 
UV-Vis is spectroscopy using the extinction coefficient: 
E444=38,900 M- 1 cm- 1 . 
Isotope Labeling of DNA 
Substrate 3'-phosphorothioate-( dT)3 was radioactively 65 
labeled with 32P-phosphate at the 5'-end to allow monitoring 
of product formation. End labeling was accomplished by 
Polyacrylamide Gel Electrophoresis 
Freeze-dried reaction samples were resuspended in 50 µI 
of a 7 M urea solution and loaded on to a 40 cmx50 cm, 
denaturing 30% polyacrylamide gel (19:l::acrylamide:bi-
sacrylamide). As oligonucleotide length standards, a sample 
containing 32P-end-labled (dT)8 , 32P-end-labled (dT)7 and 
32P-end-labled (dT)6 were loaded in gel lanes flanking the 
reaction samples. Polyacrylamide gels were subject to elec-
trophoresis at a constant power of 60 W for 6 hours. 
Analysis of Product Yield by Proflavine-enhanced 
Temple-directed Synthesis 
The relative yield of ( dT)7 product for each reaction was 
determined by imaging the polyacrylamide gel on a Fuji 
Phosphorlmager and quantifying the integrated intensity of 
gel bands in each lane that corresponded to the ( dT)7 ligation 
product using the software package Image Gauge V3.12. 
Background correction was accomplished by subtracting 
from all reaction samples the integrated intensity of an area 
in a control lane run with only 32P-end-labeled (dT)3 . 
A polyacrylamide gel of this set of experiments demon-
strates that product yield is enhanced by the presence of 
proflavine (FIG. 7). A plot of integrated intensities for 
product bands as a function of proflavine concentration 
further illustrates that the template-directed synthesis of 
( dT)7 is enhanced in a cooperative manner with respect to 
proflavine concentration. Maximum yield was obtained at a 
concentration of200 µM proflavine (FIG. 7). This maximum 
yield corresponds to approximately a 1000-fold increase in 
product formation with respect to the control reaction that 
contains all components of the proflavine ligation reactions, 
except proflavine (Table 1). 
TABLE 1 
Cd Th yield as a function of reaction components.a 
substrates 
3'-P03S-dT3 ; template Proflavine 
5'-I-dT4 dA16 concentration (dThyieldb 
+ 0 <20 
+ + 0 <20 
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TABLE I-continued 
(dT)i yield as a function of reaction components.a 
substrates 
3'-P03S-dT3 ; template 
5'-I-dT4 dA16 
+ 
+ + 
Proflavine 
concentration 
140 µM 
140 µM 
(dThyieldb 
-100 
13,917 
aDetails of experimental conditions for the data of this table are given in 
Example 1. 
bProduct yield Wlits correspond to integrated radioactivity intensities of 
(dT)7 bands in a polyacrylamide gel. 
10 
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template. Quantification of product yield was determined by 
the same method as that described in Example 1. A plot of 
( dT)7 product yield as a function of proflavine concentration, 
using the modified RNA template strand, is shown in FIG. 
10. 
Example 4 
In this example, the present disclosure as previously 
described in Examples 1, 2, & 3, can be applied here using 
a different intercalator, specifically coralyne (FIG. 11). 
Using coralyne as the intercalator provides for the use of a 
triplex system instead of the previously described duplex 
The example given is to illustrate the disclosure and is not 
intended to limit the claims of the disclosure in any manner. 
One skilled in the art will appreciate from reading this 
disclosure that various changes in form and detail can be 
made without departing from the true scope of the disclo-
sure. 
15 system. Hoogsteen base pairing was used to align the 
substrates on the duplex template (FIG. 12). 
Synthesis and Purification of Oligonucleotides 
Synthesis and purification of oligonucleotides were as 
20 
described in Examples 1, 2, & 3. The particular template, 
however, was synthesized as a duplex (hairpin-shaped). 
Example 2 Ligation Reactions and Results 
In this example, a template with an RNA backbone is used 
to guide the assembly of substrate oligonucleotides to yield 
a product strand with a DNA backbone that contains a single 
phosphorothioate linkage. 
Reactions were carried out in the same manner as 
described in Example 1 except for the use of coralyn as the 
25 intercalator. Gel electrophoresis data for the triplex system 
using coralyne are shown in FIG. 13. 
Synthesis and Purification of Oligonucleotides 
The RNA template strand, (rA) 16 , was purchased from 
Dharmacon (Boulder, Co.) as a 1 micromole synthesis, 30 
deprotected following manufacture's protocol and purified 
by passage over a 1 m G-15 size-exclusion column. After 
passage over the column, sample fractions corresponding to 
the largest molecular weight products were pooled and 
freeze-dried. A stock solution of (rA)16 was prepared by 35 
resuspending the freeze-dried RNA in 1 ml of dH20. The 
substrate oligonucleotides 5'-iodo-(dT)4 and 32P-labeled-3'-
phosphorotioate-( dT)3 were prepared as described in 
Example 1. 
Ligation Reactions and Results 40 
Reactions were carried out in an identical manner as 
described in Example 1, except that the (rA) 16 RNA template 
strand was substituted for the DNA (dA)16 template strand. 
Quantification of product yield was determined by the same 
method as that described in Example 1. A plot of ( dT)7 45 
product yield as a function of proflavine concentration, 
using an RNA template strand, is shown in FIG. 8. 
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<160> NUMBER OF SEQ ID NOS, 9 
<210> SEQ ID NO 1 
<211> LENGTH, 4 
<212> TYPE, DNA 
SEQUENCE LISTING 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic substrate strand 
<400> SEQUENCE, 1 
tcga 
<210> SEQ ID NO 2 
<211> LENGTH, 3 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic substrate strand 
<400> SEQUENCE, 2 
etc 
<210> SEQ ID NO 3 
<211> LENGTH, 4 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic substrate strand 
<400> SEQUENCE, 3 
cgta 
<210> SEQ ID NO 4 
<211> LENGTH, 11 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic template strand 
<400> SEQUENCE, 4 
agctgcatga g 
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-continued 
<210> SEQ ID NO 5 
<211> LENGTH, 11 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, product strand, combined SEQ ID Nos. 1, 2, 
and 3 
<400> SEQUENCE, 5 
tcgacgtact c 
<210> SEQ ID NO 6 
<211> LENGTH, 3 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic substrate strand 
<400> SEQUENCE, 
ttt 
<210> SEQ ID NO 7 
<211> LENGTH, 4 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic substrate strand 
<400> SEQUENCE, 7 
tttt 
<210> SEQ ID NO 8 
<211> LENGTH, 23 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, synthetic template hairpin 
<400> SEQUENCE, 8 
gcaaaaaaag gaactttttt tgc 
<210> SEQ ID NO 9 
<211> LENGTH, 7 
<212> TYPE, DNA 
<213> ORGANISM, Artificial sequence 
<220> FEATURE, 
11 
3 
4 
23 
<223> OTHER INFORMATION, product strand, combined Seq ID Nos 6 and 7 
<400> SEQUENCE, 9 
ttttttt 
I claim: 
1. A method of synthesizing a polynucleotide comprising: 
(a) combining in a fluid: 
(1) a template, 
(2) a plurality of nucleic acid subunits, and 
55 
(3) an intercalator selected from the group consisting of 60 
proflavine and coralyne; and 
(b) chemically ligating adjacent nucleic acid subunits 
associated with the template, wherein the chemical 
ligation is not medicated by an enzyme. 
2. The method of claim 1, wherein the intercalator stabi- 65 
lizes sequence specific associations between nucleic acid 
subunits and the template. 
7 
3. The method of claim 1, wherein the intercalator com-
prises a planar, polycyclic moiety. 
4. The method of claim 1, wherein the intercalator com-
prises a planar, tricyclic moiety. 
5. The method of claim 1, wherein the intercalator com-
prises proflavine. 
6. The method of claim 1, wherein the intercalator facili-
tates sequence specific interaction between the plurality of 
nucleic acid subunits and the template. 
7. The method of claim 1, wherein at least one of the 
plurality of nucleic acid subunits is modified to contain a 
reactive chemical group. 
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8. The method of claim 1, wherein at least one of the 
plurality of nucleic acid subunits comprises a methyl-imi-
dazole-activated phosphate. 
9. The method of claim 1, wherein the template or at least 
one of the plurality of nucleic acid subunits comprises RNA, 
DNA, or a combination thereof. 
10. The method of claim 1, wherein the template com-
prises methylated RNA. 
11. The method of claim 1, wherein a chemical bond 
between the adjacent nucleic acid subunits is formed using 10 
a condensing agent. 
12. The method of claim 11, wherein the condensing agent 
comprises 1-(3-dimethy laminopropy 1)-3-ethy lcarboiimide. 
13. The method of claim 1, wherein a chemical bond 
15 forms spontaneously between two adjacent nucleic acid 
subunits. 
14. The method of claim 1, wherein at least one of the 
plurality of nucleic acid subunits comprises two or more 
linked nucleotides. 
15. The method of claim 1, wherein the nucleic acid 
subunits comprise a modified sugar, modified purine base, 
modified pyrimidine base, or a combination thereof. 
20 
16. The method of claim 1, wherein the synthesized 
polynucleotide is at least partially complementary to at least 25 
a portion of the template. 
17. A method of synthesizing a polynucleotide compris-
ing: 
(a) combining in a fluid: 
(1) a template comprising a methylated RNA, 
(2) a plurality of nucleic acid subunits, and 
(3) an intercalator comprising proflavine; and 
30 
(b) chemically ligating adjacent nucleic acid subunits 
associated with the template, wherein the chemical 
35 ligation is not medicated by an enzyme. 
18. The method of claim 17, wherein the intercalator 
stabilizes sequence specific associations between the nucleic 
acid subunits and the template. 
19. The method of claim 17, wherein the intercalator 40 
facilitates sequence specific interaction between the plural-
ity of nucleic acid subunits and the template. 
40 
28. A method of synthesizing a polynucleotide compris-
ing: 
(a) combining a template, an intercalator, and a plurality 
of nucleic acid subunits in a fluid, wherein the inter-
calator has a structure according to Formula I: 
Formula! 
wherein each R1 and R4 are C; 
R2 is independently NH2 or N(CH3 ) 2 ; 
R3 is N; 
R5 and R6 are H; and 
(b) chemically ligating the subunits together to form a 
polynucleotide that is complementary to at least a 
portion of the template, wherein the chemical ligation 
is not medicated by an enzyme. 
29. The method of claim 28, wherein the intercalator 
comprises proflavine. 
30. The method of claim 28, wherein the intercalator 
facilitates sequence specific interaction between the plural-
ity of nucleic acid subunits and the template. 
31. The method of claim 28, wherein the nucleic acid 
subunits are modified to contain a reactive chemical group. 
32. The method of claim 28, wherein at least one nucleic 
acid subunit comprises a methyl-imidazole-activated phos-
phate. 
33. The method of claim 28, wherein the template or at 
least one nucleic acid subunit comprises RNA, DNA, or a 
combination thereof. 
34. The method of claim 28, wherein the template com-
prises methylated RNA. 
35. The method of claim 28, wherein a chemical bond 
between the nucleic acid subunits is formed using a con-
densing agent. 
20. The method of claim 17, wherein at least one of the 
plurality of nucleic acid subunits are modified to contain a 
reactive chemical group. 
36. The method of claim 35, wherein the condensing 
agent comprises 1-(3-dimethy laminopropy 1)-3-ethy lcarboi-
45 imide. 
21. The method of claim 17, wherein at least one of the 
plurality of nucleic acid subunits comprises a methyl-imi-
dazole-activated phosphate. 
22. The method of claim 17, wherein at least one of the 
plurality of nucleic acid subunits comprises RNA, DNA, or 50 
a combination thereof. 
23. The method of claim 17, wherein a chemical bond 
between the adjacent nucleic acid subunits is formed using 
a condensing agent. 
55 
24. The method of claim 23, wherein the condensing 
agent comprises 1-(3-dimethy laminopropy 1 )-3-ethy lcarboi-
imide. 
25. The method of claim 17, wherein a chemical bond 
forms spontaneously between at least two adjacent nucleic 60 
acid subunits. 
26. The method of claim 17, wherein at least one of the 
plurality of nucleic acid subunits comprises a modified 
sugar, purine base or pyrimidine base. 
27. The method of claim 17, wherein the intercalator is 65 
cationic, anionic, or neutral under conditions that form the 
chemical bond between the nucleic acid subunits. 
37. The method of claim 28, wherein a chemical bond 
forms spontaneously between two adjacent nucleic acid 
units. 
38. The method of claim 28, wherein at least one of the 
nucleic acid subunits comprises two or more monomers. 
39. The method of claim 28, wherein at least one of the 
plurality of nucleic acid subunits comprises a modified 
sugar, purine base or pyrimidine base. 
40. A method of selecting a polynucleotide comprising: 
(a) generating a plurality of polynucleotides having a 
random sequence of monomers flanked by predeter-
mined sequences of monomers; 
(b) selecting a subset of the plurality of the polynucle-
otides based on binding affinity to a target; and 
( c) synthesizing product polynucleotides by intercalator-
meditated template-directed synthesis using the subset 
as templates, wherein the intercalator-meditated tem-
plate-directed synthesis comprises combining in a fluid 
the templates, a plurality of nucleic acid subunits, and 
an intercalator selected from the group consisting of 
proflavine and coralyne, and chemically ligating adja-
US 7,368,560 B2 
41 
cent nucleic acid subunits associated with the tem-
plates, wherein the chemical ligation is not medicated 
by an enzyme. 
41. The method of claim 40, further comprising the step 
of sequencing the product polynucleotides. 
42. The method of claim 40, further comprising the step 
of amplifying the product polynucleotides. 
43. The method of claim 42, further comprising the step 
of generating a second plurality of polynucleotides by 
intercalator-meditated template-directed synthesis using the 10 
amplified product polynucleotides as templates. 
44. The method of claim 43, further comprising the step 
of selecting a subset of the second plurality of polynucle-
otides based on binding affinity to the target. 
42 
45. The method of claim 44, further comprising the step 
of sequencing the subset of the second plurality of poly-
nucleotides. 
46. The method of claim 45, further comprising the step 
of synthesizing a second set of product polynucleotides by 
intercalator-meditated template-directed synthesis using the 
selected subset of the second plurality of polynucleotides of 
claim 45 as templates. 
47. The method of claim 46, further comprising the step 
of sequencing the second set of product polynucleotides 
synthesized in claim 46. 
* * * * * 
